Content
Yahoo Finance Community
09/17
Comment
If the management wants to spook the PACB short sellers they would need to show some indications of increased revenue to come. The shorts wouldn't give a flying hoot about scientific collaboartions, or technical achievements if no revenue boost is to follow. Revenue man... revenue!...
Votes:
2
0
Yahoo Finance Community
09/17
Comment
Revio hi fi reads should be used in a collaboration to determine the cause of poverty and inclination to make bad bets on risky stocks. Hi fi reads can determine root cause of making bad bets thereby enabling individual investors to improve their portfolio performance....
Yahoo Finance Community
09/17
Comment
If you shorted this from the $30s you are a genius if you kept that until $1 plus, congratulations! Same if you shorted from $12s. However, if you are shorting now in one and two bucks not only are you way too late but you’re about to get burned alive as the fire has just started. Live and learn grasshopper....
Votes:
2
0
Yahoo Finance Community
09/17
Comment
I am conjuring up my mistakes with Skyworks to keep me holding this stock..I began to sell off Skyworks and each time an expert opinion prompted me to sell, it's tapped out, or it's years out from any real return, I got BURNED. If I would've held it..oh man..it still hurts...
Votes:
2
0
Yahoo Finance Community
09/19
Comment
Serious question to all of you regulars calling out price targets, please, explain to me the fundamentals to how you get to your figures. I am long by the way, i just find it hilarious you all think the boogieman is out here trying to hold a stock down that will burn through all of its cash in less than 5 quarters as is, without diluting shareholders further or carrying even more debt....
Votes:
1
1
Yahoo Finance Community
09/19
Comment
Realistically speaking- CEO had to cover his taxes on RSU’s. Wouldn’t read much into his sell. Too much potential here to sell at the $2 mark. Could very easily see $3 by end of month and $5 by end of year. No reason PACB can’t 50X to Illumina’s market cap. They’re trending in the right direction and it’s only up from here. Whoever got in below $1.30 10 days ago is sitting better than pretty....
Votes:
4
1
Yahoo Finance Community
09/23
Comment
The problem with this company is that its CEO and BOD is under the impression that if he can improve on loss per share (-EPS) things will become hunky dory again, so they lay some people off and turn off extra lights and cut out the free coffee. What he is missing is that the investors couldn't care less if the loss per share improves and yet the revenue drops.Declining revenue is what causes compnies to go belly up!...
Votes:
2
0
Yahoo Finance Community
09/23
Comment
I think PACB is AMD, and ILMN is INTC. Way back in 2015, AMD was like around 1.50 or something, and AMD is now bigger than INTC. The market did not want AMD to die and INTC monopoly of the CPU market. I think PACB will not die here. Maybe it is a good bet for the long run. what do you folks think?...
Votes:
1
0
Yahoo Finance Community
09/24
Comment
Yesterday ARKK made only one purchase. think about that. ONE purchase yesterday and that was PACB. $675,489 dollars worth! At the same time, Cathie sold off $9,158,500 million of TSLA, $7,620,440 of ROKU, $4,076,574 of RBLX, $2,592,107 of CRSP and basically every other holding. We might cry shortrun and we might have to listen to Green machine, Mihael, Zarko, zell and every other disgruntled or manipulating short seller. But we will win this tug of war?...
Votes:
2
0
Yahoo Finance Community
09/24
Comment
looks guys, i hate to bring real news, but pacbio management basically lied. when they say "the environment is challenging, customers pushing out". they really mean the purchase isn't a basic necessity. Customer don't need it critically so they're not buying.we need something like the last covid which sparked the investment cycle....
Votes:
1
3
Yahoo Finance Community
09/24
Comment
I’m sure the PACB board is following Mihael’s words carefully. So incredibly smart and talented. Owned 50,000 shares (apparently), now zero because PACB is going bankrupt. But says “still a worth a bet if it falls to $1.20 per share”. Only if every company could have someone that intelligent as a stock holder, and even more, an advisor nobody asked for....
Votes:
4
0
Yahoo Finance Community
09/25
Comment
ARKK INNOVATION made only one purchase yesterday. Guess what that was... Yes, our dearly beloved, she bought 988,404 shares with a value of 1, 709,939. Cathie Is definitely chewing up all the available shares. So if there is any squeeze coming it could be massive. Obviously, SARK Is gambling today and doubling down on their short position along with the other short sellers. Never a dull day with PACB...
Votes:
4
0
Yahoo Finance Community
09/25
Comment
they think sales environment would be huge and less restrictive in a recession. best we can do is trade around pennies for another year while cathy and others play trading games. Meanwhile everyone hopes the "we built it, they will come" mantra will play out somehow....
Yahoo Finance Community
09/25
Comment
I can take a drop in share price, but this is ridiculous being no bad news, good news we had with Asian market. But I see a drop then large purchase. Only thing we get shorts buying 20k shares and turn around and sell them lower at 500 share clips to drive price down, bunch of crooks....
Votes:
4
1
Yahoo Finance Community
09/26
Comment
I'm going with the flow due to Cathie Wood and picked up some a few hours ago. I stay away from penny biotechs, but the price and big money behind goes in favor of those staking a position now. Any positive news will pop this thing up and bring in the influential trading clubs....
Votes:
4
1
Yahoo Finance Community
09/27
Comment
If rumors about Q3 revenue beating expectations are true it might soar back to $3+ even before the next earnings report is revealed. As someone pointed out, lower interest rates will help small caps with debt to refinance their debt and invest further into growth. There is another aspect. Lowering interest rates should help PACB sales ramp up. If revenue goes up sooner than previously expected it could go back towards double digit price per share quickly. There are some signs that clinical adoption is happening faster than anticipated. That alone can propel this stock 1000% easily once revenue figures start reflecting that reality....
Votes:
4
3
Quantexa News
09/27
Benjamin F. Edwards & Company Inc. Acquires 139,408 Shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB)
Benjamin F. Edwards & Company Inc. lifted its holdings in Pacific Biosciences of California, Inc. (NASDAQ:PACB – Free Report) by 5,755.9% in the 2nd quarter, Holdings Channel reports. The firm owned 1...
Quantexa News
09/30
Is Pacific Biosciences of California Inc (NASDAQ: PACB) Stock Poised for More Growth?
In the last trading session, 4.78 million Pacific Biosciences of California Inc (NASDAQ:PACB) shares changed hands as the company's beta touched 2.04. With the company's per share price at $1.75 chang...
Yahoo Finance Community
09/30
Comment
PACB has 272530000 shares . if PACB has a market capital of 1B. It will be 3.66 per share. It is achieable. But PACB has 100 million shares more than ILMN. Let hope PACB does create more shares to have capital for running the company. Burning cash is the problem for this company right now. But it could be acquired by someone anytime now....
Votes:
1
1
Yahoo Finance Community
10/02
Comment
Well.... Cathie sold over $9 million worth of Tesla on September 24 while purchasing 1.7 million worth of PACB. Yesterday she sold an additional $7.27 million worth of Tesla . I would say that was a good call considering the drop Tesla is taking today for example . Lucky or inside information?...
Votes:
6
0
Quantexa News
10/03
Comparing Pacific Biosciences of California (NASDAQ:PACB) & Prenetics Global (NASDAQ:PRE)
Pacific Biosciences of California (NASDAQ:PACB – Get Free Report) and Prenetics Global (NASDAQ:PRE – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will con...
Quantexa News
10/03
Comparing Prenetics Global (NASDAQ:PRE) and Pacific Biosciences of California (NASDAQ:PACB)
Pacific Biosciences of California (NASDAQ:PACB – Get Free Report) and Prenetics Global (NASDAQ:PRE – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will con...
Quantexa News
10/03
Pacific Biosciences of California, Inc. Is Being Investigated For Securities Law Violations And The Schall Law Firm Encourages Shareholder Participation
LOS ANGELES, CA / ACCESSWIRE / October 3, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Bioscie...
Quantexa News
10/04
Should You Expect Pacific Biosciences of California Inc (NASDAQ:PACB) To Recover From Its 28.83% Gain From Highs?
Pacific Biosciences of California Inc (NASDAQ:PACB)'s traded shares stood at 2.78 million during the last session, with the company's beta value hitting 2.05. At the close of trading, the stock's pric...
Quantexa News
10/04
Investors Are Invited To Join The Schall Law Firm's Inquiry Into Pacific Biosciences of California Inc For Possible Securities Fraud
LOS ANGELES, CA / ACCESSWIRE / October 4, 2024 / The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Pacific Bioscie...
Yahoo Finance Community
10/07
Comment
The global Long Read Sequencing Market is expected to grow from USD 758 million in 2024 to USD 3,129 million in 2029, at a CAGR of 32.8%. Technological innovations, particularly the integration of AI for improved data analysis and mutation detection, enhance the effectiveness and accessibility of long-read sequencing....
Votes:
4
0
Quantexa News
10/07
seqWell Announces LongPlex Long Fragment Multiplexing Kit Launch to Address
seqWell, a leading global provider of genomic library and multiplexing solutions, today announced the full commercial launch of its , a first-in-class tagmentation product designed to address the scal...
Quantexa News
10/07
seqWell Announces LongPlex Long Fragment Multiplexing Kit Launch to Address Workflow Challenges in Long-Read Sequencing
seqWell is designated as a PacBio Compatible Partner with novel tagmentation-based workflow that improves throughput and scalability of long read assays. BEVERLY, Mass.--( BUSINESS WIRE )--seqWell, a...
Quantexa News
10/10
PacBio to Report Third Quarter 2024 Financial Results on November 7, 2024
MENLO PARK, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2024 financial results on Thurs...
Quantexa News
10/10
PacBio to Report Third Quarter 2024 Financial Results on November 7, 2024
MENLO PARK, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2024 financial results on Thurs...
Quantexa News
10/10
PacBio to Report Third Quarter 2024 Financial Results on November 7, 2024
PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2024 financial results on Thursday, November 7, 2024, at 4:30 pm Eastern Time. The...
Quantexa News
10/10
PacBio to Report Third Quarter 2024 Financial Results on November 7, 2024
MENLO PARK, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2024 financial results on Thurs...
Quantexa News
10/10
PacBio to Report Third Quarter 2024 Financial Results on November 7, 2024
MENLO PARK, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2024 financial results on Thurs...
Quantexa News
10/10
PacBio to Report Third Quarter 2024 Financial Results on November 7, 2024
MENLO PARK, Calif., Oct. 10, 2024 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its third quarter 2024 financial results on Thursd...
Quantexa News
10/11
PacBio Enters Cancer Genomics Research Collaboration in Singapore with Advanced Onso Sequencing
SINGAPORE, Oct. 11, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the signing of a new Research Collaborati...
Quantexa News
10/11
PacBio Enters Cancer Genomics Research Collaboration in Singapore with Advanced Onso Sequencing
SINGAPORE , Oct. 11, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the signing of a new Research Collaborat...
Quantexa News
10/11
PacBio Enters Cancer Genomics Research Collaboration in Singapore with Advanced Onso Sequencing
SINGAPORE, Oct. 11, 2024 (GLOBE NEWSWIRE) -- PacBio PACB, a leading developer of high-quality, highly accurate sequencing solutions, today announced the signing of a new Research Collaboration Agreeme...
Quantexa News
10/11
PacBio Enters Cancer Genomics Research Collaboration in Singapore with Advanced Onso Sequencing
Groundbreaking collaboration to unlock the full potential of PacBio’s Onso technology, accelerating breakthroughs in cancer genomics across Asia SINGAPORE, Oct. 11, 2024 (GLOBE NEWSWIRE) -- PacBio (N...
Quantexa News
10/11
PacBio Enters Cancer Genomics Research Collaboration in Singapore with Advanced Onso Sequencing
PacBio Groundbreaking collaboration to unlock the full potential of PacBio’s Onso technology, accelerating breakthroughs in cancer genomics across Asia SINGAPORE, Oct. 11, 2024 (GLOBE NEWSWIRE) -- P...
Quantexa News
10/11
PacBio Enters Cancer Genomics Research Collaboration in Singapore with Adva
SINGAPORE, Oct. 11, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the signing of a new Research Collaborati...
Quantexa News
10/11
PacBio Enters Cancer Genomics Research Collaboration in Singapore with Advanced Onso Sequencing
SINGAPORE, Oct. 11, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the signing of a new Research Collaborati...
Quantexa News
10/11
PacBio Enters Cancer Genomics Research Collaboration in Singapore with Advanced Onso Sequencing
SINGAPORE, Oct. 11, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the signing of a new Research Collaborati...
Quantexa News
10/11
PacBio Enters Cancer Genomics Research Collaboration in Singapore with Advanced Onso Sequencing
SINGAPORE, Oct. 11, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the signing of a new Research Collaborati...
Yahoo Finance News
10/11
Pacific Biosciences of California Signs Cancer Research Collaboration in Singapore; Shares Rise
PREMIUM Pacific Biosciences of California Signs Cancer Research Collaboration in Singapore; Shares Rise MT Newswires Fri, Oct 11, 2024, 9:58 AM In This Article: PACB +27.74% Pacific Biosciences of Cal...
Quantexa News
10/11
PacBio Enters Cancer Genomics Research Collaboration in Singapore with Advanced Onso Sequencing
Groundbreaking collaboration to unlock the full potential of PacBio's Onso technology, accelerating breakthroughs in cancer genomics across Asia SINGAPORE, Oct. 11, 2024 (GLOBE NEWSWIRE) — PacBio (NA...
Quantexa News
10/11
PacBio Enters Cancer Genomics Research Collaboration in Singapore with Advanced Onso Sequencing
Groundbreaking collaboration to unlock the full potential of PacBio’s Onso technology, accelerating breakthroughs in cancer genomics across Asia PacBio (NASDAQ: PACB), a leading developer of high-qual...
Quantexa News
10/11
PacBio Enters Cancer Genomics Research Collaboration in Singapore with Advanced Onso Sequencing
Groundbreaking collaboration to unlock the full potential of PacBio's Onso technology, accelerating breakthroughs in cancer genomics across Asia SINGAPORE, Oct. 11, 2024 (GLOBE NEWSWIRE) -- PacBio (N...
Yahoo Finance Community
10/11
Comment
So who bought yesterday and reduced their cost average? Is $2 plus a possibility in the near future, wouldn't that be fun again? Personally waiting around for a few quarters anyway, and on dips will continue to add....... wishing the best for all longs....
Votes:
2
0
Quantexa News
10/11
PacBio Enters Cancer Genomics Research Collaboration in Singapore with Advanced Onso Sequencing
Groundbreaking collaboration to unlock the full potential of PacBio's Onso technology, accelerating breakthroughs in cancer genomics across Asia SINGAPORE — PacBio (NASDAQ: PACB), a leading developer...
Quantexa News
10/11
Pacific Biosciences (PACB): A Promising Surge Amidst Cancer Research Innovations
Recent Market Performance On Friday, Pacific Biosciences of California, Inc. (NASDAQ: PACB) experienced a notable surge in its stock price, climbing 27.68% to $1.98 by 02:03 PM EDT. This upward movem...
Yahoo Finance Community
10/11
Comment
In my opinion, the timing of the quarterly conference call (a day after ASHG kick-off) was the big driver in today's price action. It strongly suggests that a major announcement will occur on the first day of ASHG, most likely being the launch of the benchtop long-read sequencer. The pricing of the sequencer will really determine enthusiasm. My assumption is that it will be able to sequence a single 25M chip/day. If Pacbio can keep the price tag around $50K, it will make major waves in the academic space. However, $100K is more likely, IMO, given the price for a Revio (I believe it is currently around $400K, feel free to correct me on that)....
Votes:
7
0
Quantexa News
10/11
Pacific Biosciences of California (NASDAQ:PACB) Stock Price Up 18.4% - Here's Why
Shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB - Get Free Report) were up 18.4% during trading on Friday . The company traded as high as $1.85 and last traded at $1.84. Approximately 7...
Quantexa News
10/11
PacBio to collaborate with National Cancer Centre of Singapore on cancer profiling
Sequencing firm PacBio has signed a research collaboration agreement with the National Cancer Centre of Singapore to advance cancer research by profiling the cancer types that are prevalent in Asia....
Yahoo Finance News
10/14
PacBio Shares Rise After NCCS Partnership for Cancer Genomics Research
PacBio Shares Rise After NCCS Partnership for Cancer Genomics Research Zacks Equity Research Mon, Oct 14, 2024, 10:23 AM 4 min read In This Article: DGX +0.23% AVAH +4.55% PACB +2.44% RDNT +0.20% Paci...
Quantexa News
10/14
PacBio Shares Rise After NCCS Partnership for Cancer Genomics Research
Pacific Biosciences, Inc. PACB, popularly known as PacBio, has signed a new Research Collaboration Agreement with the National Cancer Centre of Singapore (NCCS) to enhance Asian cancer research. Lever...
Quantexa News
10/14
Pacific Biosciences of California (NASDAQ:PACB) Shares Gap Down - Here's What Happened
Pacific Biosciences of California, Inc. (NASDAQ:PACB - Get Free Report)'s share price gapped down before the market opened on Monday . The stock had previously closed at $1.98, but opened at $1.87. Pa...
Quantexa News
10/15
Reasons to Retain PacBio Stock in Your Portfolio for Now
Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, has been gaining from its continued focus on research and development. The optimism, led by decent second-quarter 2024 earnings...
Quantexa News
10/16
Barclays Keeps Their Hold Rating on Pacific Biosciences (PACB)
Barclays analyst Luke Sergott maintained a Hold rating on Pacific Biosciences ( PACB – Research Report ) today and set a price target of $2.00. The company's shares closed yesterday at $2.10. Sergot...
Quantexa News
10/16
Pacific Biosciences of California (NASDAQ:PACB) Shares Down 4.8% - Should You Sell?
Pacific Biosciences of California, Inc. (NASDAQ:PACB - Get Free Report)'s stock price dropped 4.8% on Wednesday . The stock traded as low as $1.99 and last traded at $2.00. Approximately 1,328,897 sha...
Yahoo Finance News
10/16
Pacific Biosciences of California (PACB) Stock Slides as Market Rises: Facts to Know Before You Trade
Pacific Biosciences of California (PACB) Stock Slides as Market Rises: Facts to Know Before You Trade Zacks Equity Research Wed, Oct 16, 2024, 3:15 PM 3 min read In This Article: PACB -7.77% ^GSPC -0....
Yahoo Finance News
10/22
PacBio Onso™ Short Read Sequencing Instrument Joins 10x Genomics Compatible Partner Program
PacBio Onso™ Short Read Sequencing Instrument Joins 10x Genomics Compatible Partner Program PacBio PacBio Tue, Oct 22, 2024, 9:05 AM 4 min read In This Article: PACB -2.78% MENLO PARK, Calif., Oct. 22...
Yahoo Finance Community
10/22
Comment
I hope when the CEO is doing the conference call after the earnings report in a couple of weeks, he realizes that serious big money investors focus on your plans for improving the revenue. EPS can easily be manipulated to the upside by lay offs, cutting the overhead etc etc which are one time items. None of this hoopla and razmataz about scientific collaborations with this and that university is going to do a thing to the stock price if you cannot map out a plan to improve the revenue Q after Q. Revenue man...Revenue:)...
Votes:
5
0
Yahoo Finance Community
10/23
Comment
The global Long Read Sequencing Market is expected to grow from USD 758 million in 2024 to USD 3,129 million in 2029, at a CAGR of 32.8%. Technological innovations, particularly the integration of AI for improved data analysis and mutation detection, enhance the effectiveness and accessibility of long-read sequencing....
Votes:
4
1
Quantexa News
10/25
Pacific Biosciences of California Inc (PACB) last month performance of 8.18% certainly makes it a sizzling prospect
Pacific Biosciences of California Inc (NASDAQ: PACB) open the trading on Thursday, with a bit cautious approach as it glided -1.71% to $1.72, before settling in for the price of $1.75 at the close. Ta...
Yahoo Finance Community
10/28
Comment
anyone remember the wise Obama and Kerry? negotiate with Iran and let them do as they please. See how David takes care of itself (and your peace loving persia) oh wise president of all times? and kerry the experienced soldier and diplomat who just follows orders.?...
Yahoo Finance News
10/29
Pacific Biosciences of California, Inc. (NASDAQ:PACB) is a favorite amongst institutional investors who own 86%
Pacific Biosciences of California, Inc. (NASDAQ:PACB) is a favorite amongst institutional investors who own 86% editorial-team@simplywallst.com (Simply Wall St) Tue, Oct 29, 2024, 5:29 AM 4 min read I...
Yahoo Finance News
10/29
PacBio Announces SPRQ Chemistry for Revio Sequencing Systems, a Major Advance Reducing the Cost of a HiFi Human Genome to less than $500
PacBio Announces SPRQ Chemistry for Revio Sequencing Systems, a Major Advance Reducing the Cost of a HiFi Human Genome to less than $500 PacBio PacBio Tue, Oct 29, 2024, 9:05 AM 6 min read In This Art...
Quantexa News
10/29
Pacific Biosciences of California, Inc. (NASDAQ:PACB) is a favorite amongst institutional investors who own 86%
editorial-team@simplywallst.com (Simply Wall St) 4 min read In this article Key Insights Significantly high institutional ownership implies Pacific Biosciences of California's stock price is sensi...
Yahoo Finance News
10/30
Volta Labs joins PacBio Compatible program to help PacBio customers scale sequencing through automated library prep
Volta Labs joins PacBio Compatible program to help PacBio customers scale sequencing through automated library prep PR Newswire Wed, Oct 30, 2024, 8:13 AM 3 min read In This Article: PACB +0.46% BOSTO...
Yahoo Finance News
10/30
Pacific Biosciences (PACB): Promising Gene Editing Stock With Innovating Technology
Pacific Biosciences (PACB): Promising Gene Editing Stock With Innovating Technology Attiya Zainib Wed, Oct 30, 2024, 2:57 PM 6 min read In This Article: PACB +0.46% We recently published a list of 10...
Quantexa News
10/30
Azenta Obtains Regulatory Approval for Clinical Long-Read Whole Genome Sequencing Test
Werbung Traditional short-read sequencing methods often struggle with identifying genetic variants in repetitive regions of the genome that underpin many rare diseases, hindering accurate diagnoses a...
Quantexa News
10/31
Pacific Biosciences of California (PACB) to Release Quarterly Earnings on Thursday
Pacific Biosciences of California ( NASDAQ:PACB – Get Free Report ) is set to announce its earnings results after the market closes on Thursday, November 7th. Analysts expect the company to announce e...
Quantexa News
10/31
Pacific Biosciences of California (PACB) to Release Quarterly Earnings on Thursday
Pacific Biosciences of California ( NASDAQ:PACB – Get Free Report ) is scheduled to post its quarterly earnings results after the market closes on Thursday, November 7th. Analysts expect Pacific Biosc...
Quantexa News
10/31
Pacific Biosciences of California Inc (NASDAQ: PACB) – Does It Provide Stability And Growth?
Pacific Biosciences of California Inc (NASDAQ:PACB) shares, rose in value, with the stock price up by 4.85% to the previous day's close as strong demand from buyers drove the stock to $2.16. Actively...
Yahoo Finance News
10/31
Pacific Biosciences of California (PACB) Advances While Market Declines: Some Information for Investors
Pacific Biosciences of California (PACB) Advances While Market Declines: Some Information for Investors Zacks Equity Research Thu, Oct 31, 2024, 6:15 PM 2 min read In This Article: PACB +12.44% Pacifi...
Yahoo Finance News
11/04
Curious about Pacific Biosciences (PACB) Q3 Performance? Explore Wall Street Estimates for Key Metrics
YAHOO FINANCE ELECTION GUIDE What the 2024 campaign means for your wallet Curious about Pacific Biosciences (PACB) Q3 Performance? Explore Wall Street Estimates for Key Metrics Zacks Equity Research M...
Quantexa News
11/04
Curious about Pacific Biosciences (PACB) Q3 Performance? Explore Wall Street Estimates for Key Metrics
Wall Street analysts expect Pacific Biosciences of California (PACB) to post quarterly loss of $0.20 per share in its upcoming report, which indicates a year-over-year increase of 25.9%. Revenues are...
Quantexa News
11/05
Pacific Biosciences of California (PACB) Set to Release Quarterly Earnings on Thursday
Pacific Biosciences of California (NASDAQ:PACB – Get Free Report) is scheduled to issue its quarterly earnings data after the market closes on Thursday, November 7th. Analysts expect the company to an...
Quantexa News
11/05
Pacific Biosciences of California (PACB) to Release Quarterly Earnings on Thursday
Pacific Biosciences of California ( NASDAQ:PACB – Get Free Report ) is scheduled to be posting its quarterly earnings results after the market closes on Thursday, November 7th. Analysts expect Pacific...
Yahoo Finance News
11/06
Pacific Biosciences of California Inc (PACB) Q3 2024 Earnings Report Preview: What To Expect
FED CUTS Fed slashes interest rates by 25 basis points in 2nd consecutive cut Pacific Biosciences of California Inc (PACB) Q3 2024 Earnings Report Preview: What To Expect GuruFocus News Wed, Nov 6, 20...
Quantexa News
11/06
Pacific Biosciences of California Inc (PACB) Q3 2024 Earnings Report Preview: What To Expect
Pacific Biosciences of California Inc (NASDAQ:PACB) is set to release its Q3 2024 earnings on Nov 7, 2024. The consensus estimate for Q3 2024 revenue is $41.95 million, and the earnings are expected t...
Polygon News
11/06
PacBio Unveils the Vega System, a New Sequencing Platform Bringing HiFi to the Benchtop
PacBio has announced the launch of Vega, a benchtop long-read sequencing platform priced at $169,000. Vega is designed to make highly accurate long-read sequencing accessible to a broader range of res...
Quantexa News
11/06
PacBio Unveils the Vega System, a New Sequencing Platform Bringing HiFi to the Benchtop
MENLO PARK, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, today announced the Vega™ system , the company's first benc...
Quantexa News
11/06
PacBio Unveils the Vega System, a New Sequencing Platform Bringing HiFi to the Benchtop
Priced at just $169,000 Vega is designed to make highly accurate long-read sequencing accessible to any laboratory MENLO PARK, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), develop...
Quantexa News
11/06
PacBio Unveils the Vega System, a New Sequencing Platform Bringing HiFi to the Benchtop
November 06, 2024 at 10:35 pm EST MENLO PARK, Calif. Nov. 06, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, today announced the Vega™...
Quantexa News
11/06
PacBio Unveils the Vega System, a New Sequencing Platform Bringing HiFi to the Benchtop
PacBio 6 min read In this article Priced at just $169,000 Vega is designed to make highly accurate long-read sequencing accessible to any laboratory MENLO PARK, Calif., Nov. 06, 2024 (GLOBE NEWSWI...
Quantexa News
11/06
PacBio Unveils the Vega System, a New Sequencing Platform Bringing HiFi to the Benchtop
MENLO PARK, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, today announced the Vega™ system, the company's first bench...
Quantexa News
11/06
PacBio Unveils the Vega System, a New Sequencing Platform Bringing HiFi to the Benchtop
MENLO PARK, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world’s most advanced sequencing technologies, today announced the Vega™ system, the company’s first bench...
Quantexa News
11/06
PacBio Unveils the Vega System, a New Sequencing Platform Bringing HiFi to the Benchtop
Priced at just $169,000 Vega is designed to make highly accurate long-read sequencing accessible to any laboratory MENLO PARK, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), develop...
Quantexa News
11/06
PacBio Unveils the Vega System, a New Sequencing Platform Bringing HiFi to the Benchtop
MENLO PARK, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, today announced the Vega™ system , the company's first benc...
Quantexa News
11/06
PacBio Unveils the Vega System, a New Sequencing Platform Bringing HiFi to the Benchtop
Priced at just $169,000 Vega is designed to make highly accurate long-read sequencing accessible to any laboratory MENLO PARK, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), develop...
Quantexa News
11/06
PacBio Unveils the Vega System, a New Sequencing Platform Bringing HiFi to the Benchtop
Priced at just $169,000 Vega is designed to make highly accurate long-read sequencing accessible to any laboratory MENLO PARK, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) — PacBio (NASDAQ: PACB), develope...
Quantexa News
11/06
Pacbio Unveils The Vega System, A New Sequencing Platform Bringing Hifi To The Benchtop
MENAFN - GlobeNewsWire - Nasdaq) Priced at just $169,000 Vega is designed to make highly accurate long-read sequencing accessible to any laboratory MENLO PARK, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE)...
Quantexa News
11/07
PacBio Unveils the Vega System, a New Sequencing Platform Bringing HiFi to the Benchtop
MENLO PARK, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, today announced the Vega™ system , the company's first benc...
Quantexa News
11/07
PacBio launches Vega system, a new benchtop sequencer with HiFi accuracy
PacBio, developer of the world’s most advanced sequencing technologies, has announced the Vega ™ system, the company’s first benchtop long-read sequencing platform. Vega delivers all the functionality...
Quantexa News
11/07
Pacific Biosciences Of California Q3 24 Earnings Conference Call At 4:30 PM ET
Pacific Biosciences of California, Inc. (PACB) will host a conference call at 4:30 PM ET on November 7, 2024, to discuss Q3 24 earnings results. To access the live webcast, log on to https://investor...
Quantexa News
11/07
PacBio Unveils the Vega System, a New Sequencing Platform Bringing HiFi to the Benchtop
Priced at just $169,000 Vega is designed to make highly accurate long-read sequencing accessible to any laboratory MENLO PARK, Calif. — PacBio (NASDAQ: PACB), developer of the world's most advanced s...
Quantexa News
11/07
PacBio Announces a Private Convertible Exchange Transaction of $459 Million Principal Amount of 1.50% Convertible Senior Notes due 2028
MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that it has entered into a priva...
Quantexa News
11/07
PacBio Announces a Private Convertible Exchange Transaction of $459 Million Principal Amount of 1.50% Convertible Senior Notes due 2028
MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- PacBio PACB, a leading developer of high-quality, highly accurate sequencing solutions, today announced that it has entered into a privately negot...
Quantexa News
11/07
PacBio Announces a Private Convertible Exchange Transaction of $459 Million Principal Amount of 1.50% Convertible Senior Notes due 2028
November 07, 2024 at 04:03 pm EST MENLO PARK, Calif. Nov. 07, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announce...
Quantexa News
11/07
PacBio Announces a Private Convertible Exchange Transaction of $459 Million Principal Amount of 1.50% Convertible Senior Notes due 2028
MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that it has entered into a priva...
Quantexa News
11/07
PacBio Announces a Private Convertible Exchange Transaction of $459 Million Principal Amount of 1.50% Convertible Senior Notes due 2028
MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that it has entered into a priva...
Quantexa News
11/07
PacBio Announces Third Quarter 2024 Financial Results GlobeNewsWire Today at 4:05pm EST
MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended September 30, 2024. Third quarter results: Gross profit, operatin...
Quantexa News
11/07
PacBio Announces a Private Convertible Exchange Transaction of $459 Million Principal Amount of 1.50% Convertible Senior Notes due 2028
MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that it has entered into a priva...
Quantexa News
11/07
PacBio reports Q3 EPS (22c), consensus (22c) Reports Q3 revenue $39.97M, consensus $41.95M. “While PacBio (PACB) continued to operate in a difficult macro environment for...
PacBio reports Q3 EPS, consensus Reports Q3 revenue $39.97 M, consensus $41.95 M.“ While PacBio continued to operate in a difficult macro environment for......
Quantexa News
11/07
Pacific Biosciences Of California, Inc. Q3 Loss Decreases, Beats Estimates
Pacific Biosciences of California, Inc. (PACB) reported Loss for third quarter that decreased from the same period last year and beat the Street estimates. The company's bottom line came in at -$60.7...
Quantexa News
11/07
Pacific Biosciences of California : PacBio Announces a Private Convertible Exchange Transaction of $459 Million Principal Amount of 1.50% Convertible Senior Notes due 2028 Form 8 K
PacBio Announces a Private Convertible Exchange Transaction of $459 Million Principal Amount of 1.50% Convertible Senior Notes due MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ...
Quantexa News
11/07
Pacific Biosciences of California : PacBio Announces Third Quarter 2024 Financial Results Form 8 K
November 07, 2024 at 05:20 pm EST PacBio Announces Third Quarter 2024 Financial Results MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) - PacBio (NASDAQ: PACB) today announced financial results f...
Quantexa News
11/07
PacBio Announces a Private Convertible Exchange Transaction of $459 Million Principal Amount of 1.50% Convertible Senior Notes due 2028
4 min read MENLO PARK, Calif., Nov. 07, 2024 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced that it has entered...
Yahoo Finance News
11/07
Pacific Biosciences of California (PACB) Reports Q3 Loss, Misses Revenue Estimates
Pacific Biosciences of California (PACB) Reports Q3 Loss, Misses Revenue Estimates Zacks Equity Research Thu, Nov 7, 2024, 6:15 PM 3 min read In This Article: PACB -9.59% Pacific Biosciences of Califo...
Quantexa News
11/07
Pacific Biosciences Of California, Inc. Q3 Loss Decreases, Beats Estimates
Pacific Biosciences of California, Inc. (PACB) announced a narrowed loss for the third quarter, surpassing Wall Street expectations. The net loss for the company stood at $60.73 million, or $0.22 per...
Yahoo Finance News
11/07
Pacific Biosciences (PACB) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Pacific Biosciences (PACB) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates Zacks Equity Research Thu, Nov 7, 2024, 7:30 PM 2 min read In This Article: PACB -6.12% Pacific Biosciences of Cal...
Quantexa News
11/07
Pacific Biosciences (PACB) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
Pacific Biosciences of California (PACB) reported $39.97 million in revenue for the quarter ended September 2024, representing a year-over-year decline of 28.2%. EPS of -$0.17 for the same period comp...
Quantexa News
11/07
Pacific Biosciences of California, Inc. (PACB) Q3 2024 Earnings Call Transcript
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q3 2024 Earnings Conference Call November 7, 2024 4:30 PM ET Company Participants Todd Friedman - Senior Director of Investor Relations Christi...
Quantexa News
11/07
Pacific Biosciences Of California, Inc. Q3 Loss Decreases, Beats Estimates
(RTTNews) - Pacific Biosciences of California, Inc. (PACB) reported Loss for third quarter that decreased from the same period last year and beat the Street estimates. The company's bottom line came...
Quantexa News
11/07
Pacific Biosciences Of California, Inc. Q3 Loss Decreases, Beats Estimates
(RTTNews) - Pacific Biosciences of California, Inc. (PACB) reported Loss for third quarter that decreased from the same period last year and beat the Street estimates. The company's bottom line came...
Quantexa News
11/07
Pacific Biosciences of California : PacBio Q3 2024 Earnings Presentation
November 07, 2024 at 11:24 pm EST PacBio Q3 2024 Earnings Presentation November 7, 2024 Third Quarter 2024 Earnings Call Statement regarding ‐ use of non ‐ GAAP financial measures PacBio report...
Quantexa News
11/07
Pacific Biosciences of California (PACB) Reports Q3 Loss, Misses Revenue Estimates
3 min read Pacific Biosciences of California (PACB) came out with a quarterly loss of $0.17 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.27 per share...
Yahoo Finance News
11/08
Pacific Biosciences of California Inc (PACB) Q3 2024 Earnings Call Highlights: Navigating ...
Pacific Biosciences of California Inc (PACB) Q3 2024 Earnings Call Highlights: Navigating ... GuruFocus News Fri, Nov 8, 2024, 3:03 AM 4 min read In This Article: PACB -6.12% Total Revenue: $40 millio...
Quantexa News
11/08
PacBio Reports Q3 2024 Financial Results Amid Strategic Growth
Pacific Biosciences ( (PACB) ) has released its Q3 earnings. Here is a breakdown of the information Pacific Biosciences presented to its investors. Pacific Biosciences (PacBio) is a leading life scie...
Quantexa News
11/08
Barclays Reaffirms Their Hold Rating on Pacific Biosciences (PACB)
In a report released today, Luke Sergott from Barclays maintained a Hold rating on Pacific Biosciences ( PACB – Research Report ), with a price target of . The company's shares closed yesterday at $2....
Quantexa News
11/08
PACB Stock Falls Despite Q3 Earnings Beat, Revenues Decline Y/Y
Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, delivered an adjusted third-quarter 2024 loss per share of 17 cents, narrower than the year-ago quarter's loss of 27 cents. The...
Quantexa News
11/08
Wilson Sonsini Advises PacBio on $459 Million Convertible Note Exchange
On November 7, 2024, Pacific Biosciences of California, Inc. (PacBio), a leading developer of high-quality, highly accurate sequencing solutions, announced that it entered into a privately negotiated...
Yahoo Finance News
11/09
Earnings Update: Pacific Biosciences of California, Inc. (NASDAQ:PACB) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
Earnings Update: Pacific Biosciences of California, Inc. (NASDAQ:PACB) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts editorial-team@simplywallst.com (Simply Wall St...
Quantexa News
11/09
Earnings Update: Pacific Biosciences of California, Inc. (NASDAQ:PACB) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
3 min read Last week, you might have seen that Pacific Biosciences of California, Inc. NASDAQ:PACB ) released its third-quarter result to the market. The early response was not positive, with shares...
Quantexa News
11/09
Earnings Update: Pacific Biosciences of California, Inc. (NASDAQ:PACB) Just Reported Its Third-Quarter Results And Analysts Are Updating Their Forecasts
Last week, you might have seen that Pacific Biosciences of California, Inc. NASDAQ:PACB ) released its third-quarter result to the market. The early response was not positive, with shares down 5.7% to...
Quantexa News
11/09
Pacific Biosciences Faces Revenue Challenges Amid Delays but Holds Potential for Growth with New Technologies
Analyst Tejas Savant of Morgan Stanley maintained a Hold rating on Pacific Biosciences ( PACB – Research Report ), retaining the price target of $2.00. Tejas Savant's rating is based on a combination...
Quantexa News
11/11
PacBio unveils new benchtop HiFi sequencing platform
Key Highlights: PacBio announced the Vega system, the company's first benchtop long-read sequencing platform, delivering all the functionality of the Revio system into a compact, lower-throughput ben...
Quantexa News
11/11
PacBio price target lowered to $6 from $7 at Scotiabank Scotiabank lowered the firm’s price target on PacBio (PACB) to $6 from $7 and keeps an Outperform rating...
Scotiabank lowered the firm’s price target on PacBio (PACB) to $6 from $7 and keeps an Outperform rating on the shares. The firm lowered its FY24 and FY25 revenue estimates following the company’s Q3...
Quantexa News
11/11
PacBio downgraded to Neutral from Buy at UBS UBS downgraded PacBio (PACB) to Neutral from Buy with a $2 price target Published first on TheFly –...
UBS downgraded PacBio (PACB) to Neutral from Buy with a $2 price target Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>...
Quantexa News
11/11
PacBio price target raised to $2.50 from $2 at Piper Sandler
Piper Sandler raised the firm's price target on PacBio ( PACB ) to $2.50 from $2 following quarterly results. The firm keeps a Neutral rating on the shares. Published first on TheFly – the ultimate s...
Quantexa News
11/11
Pacific Biosciences of California (NASDAQ:PACB) Stock Rating Lowered by UBS Group
Pacific Biosciences of California ( NASDAQ:PACB – Get Free Report was downgraded by investment analysts at UBS Group from a “buy” rating to a “neutral” rating in a research note issued on Monday, Brie...
Quantexa News
11/11
Pacific Biosciences of California Inc (NASDAQ: PACB): The Stock For Success Over The Next Few Months
In the last trading session, 27.33 million Pacific Biosciences of California Inc (NASDAQ:PACB) shares changed hands as the company's beta touched 2.02. With the company's per share price at $2.30 chan...
Quantexa News
11/11
Scotiabank Keeps Their Buy Rating on Pacific Biosciences (PACB)
Scotiabank analyst Sung Ji Nam maintained a Buy rating on Pacific Biosciences ( PACB – Research Report ) today and set a price target of $6.00. The company's shares closed last Friday at $2.30. Ji N...
Quantexa News
11/11
PacBio price target lowered to $6 from $7 at Scotiabank
Scotiabank lowered the firm's price target on PacBio ( PACB ) to $6 from $7 and keeps an Outperform rating on the shares. The firm lowered its FY24 and FY25 revenue estimates following the company's Q...
Quantexa News
11/11
Pacific Biosciences of California (NASDAQ:PACB) Rating Lowered to “Neutral” at UBS Group
Pacific Biosciences of California ( NASDAQ:PACB – Get Free Report was downgraded by investment analysts at UBS Group from a “buy” rating to a “neutral” rating in a research note issued to investors on...
Quantexa News
11/11
Scotiabank Lowers Pacific Biosciences of California (NASDAQ:PACB) Price Target to $6.00
Pacific Biosciences of California ( – had its price objective decreased by stock analysts at Scotiabank from $7.00 to $6.00 in a research note issued to investors on Monday, reports. The firm presentl...
Quantexa News
11/11
Cathie Wood's ARK Investment buys 1.01M shares of PacBio today
20:10 EST Cathie Wood's ARK Investment buys 1.01M shares of PacBio ( PACB ) today Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>> See...
Quantexa News
11/12
Investors Purchase Large Volume of Pacific Biosciences of California Call Options (NASDAQ:PACB)
Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Get Free Report ) was the recipient of unusually large options trading activity on Monday. Investors purchased 10,101 call options on the compan...
Yahoo Finance News
11/12
Pacific Biosciences of California Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Pacific Biosciences of California Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag editorial-team@simplywallst.com (Simply Wall St) Tue, Nov 12, 2024, 4:26 AM 1 min read In This Artic...
Quantexa News
11/12
Pacific Biosciences of California Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Revenue: US$40.0m (down 28% from 3Q 2023). Net loss: US$60.7m (loss narrowed by 9.2% from 3Q 2023). US$0.22 loss per share (improved from US$0.26 loss in 3Q 2023). All figures shown in the chart ab...
Quantexa News
11/12
Pacific Biosciences of California (NASDAQ:PACB) Given New $6.00 Price Target at Scotiabank
Pacific Biosciences of California ( NASDAQ:PACB – Free Report had its price target reduced by Scotiabank from $7.00 to $6.00 in a research note released on Monday, Benzinga reports. Scotiabank current...
Quantexa News
11/12
Pacific Biosciences of California (NASDAQ:PACB) Price Target Lowered to $6.00 at Scotiabank
Pacific Biosciences of California ( NASDAQ:PACB – Free Report had its price objective decreased by Scotiabank from $7.00 to $6.00 in a research report released on Monday, Benzinga reports. Scotiabank...
Quantexa News
11/12
Pacific Biosciences of California Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
editorial-team@simplywallst.com (Simply Wall St) 1 min read In This Article Pacific Biosciences of California ( NASDAQ:PACB ) Third Quarter 2024 Results Key Financial Results Revenue: US$40.0m (...
Quantexa News
11/12
Pacific Biosciences of California (NASDAQ:PACB) Stock Price Up 5.3% After Analyst Upgrade
NASDAQ:PACB – Get Free Report ) rose 5.3% during mid-day trading on Tuesday after Piper Sandler raised their price target on the stock from $2.00 to $2.50. Piper Sandler currently has a neutral rating...
Quantexa News
11/12
Pacific Biosciences of California (NASDAQ:PACB) Trading 5.3% Higher on Analyst Upgrade
Shares of Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Get Free Report ) traded up 5.3% during trading on Tuesday after Piper Sandler raised their price target on the stock from $2.00 to $2...
Quantexa News
11/13
Pacific Biosciences of California (NASDAQ:PACB) Trading Up 5.3% After Analyst Upgrade
Pacific Biosciences of California, Inc. (NASDAQ:PACB – Get Free Report) shares were up 5.3% on Tuesday after StockNews.com upgraded the stock to a sell rating. The stock traded as high as $2.66 and la...
Quantexa News
11/13
Pacific Biosciences of California Sees Unusually High Options Volume (NASDAQ:PACB)
Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Get Free Report ) was the recipient of some unusual options trading activity on Monday. Stock traders bought 10,101 call options on the stock. T...
Quantexa News
11/13
Piper Sandler Forecasts Strong Price Appreciation for Pacific Biosciences of California (NASDAQ:PACB) Stock
Pacific Biosciences of California (NASDAQ:PACB – Get Free Report) had its target price hoisted by investment analysts at Piper Sandler from $2.00 to $2.50 in a research report issued to clients and in...
Quantexa News
11/14
Pacific Biosciences of California (NASDAQ:PACB) Shares Up 5.3% Following Analyst Upgrade
Shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB – Get Free Report) were up 5.3% on Tuesday after StockNews.com upgraded the stock to a sell rating. The stock traded as high as $2.66 and...
Quantexa News
11/14
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Given Consensus Recommendation of “Hold” by Brokerages
Shares of Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Get Free Report ) have received a consensus recommendation of “Hold” from the fifteen research firms that are covering the company, Ma...
Quantexa News
11/14
Pacific Biosciences of California (NASDAQ:PACB) Raised to Sell at StockNews.com
Pacific Biosciences of California (NASDAQ:PACB – Get Free Report) was upgraded by StockNews.com to a “sell” rating in a report issued on Tuesday. Get Pacific Biosciences of California alerts: A numb...
Quantexa News
11/14
Creative Planning Raises Stake in Pacific Biosciences of California, Inc. (NASDAQ:PACB)
Creative Planning increased its stake in shares of Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Free Report ) by 30.8% during the third quarter, according to its most recent filing with the...
Quantexa News
11/14
Scotiabank Cuts Pacific Biosciences of California (NASDAQ:PACB) Price Target to $6.00
Pacific Biosciences of California (NASDAQ:PACB – Free Report) had its price target trimmed by Scotiabank from $7.00 to $6.00 in a report issued on Monday,Benzinga reports. The brokerage currently has...
Quantexa News
11/14
Scotiabank Issues Pessimistic Forecast for Pacific Biosciences of California (NASDAQ:PACB) Stock Price
Pacific Biosciences of California (NASDAQ:PACB – Free Report) had its target price decreased by Scotiabank from $7.00 to $6.00 in a research report released on Monday morning,Benzinga reports. Scotiab...
Quantexa News
11/14
Pacific Biosciences of California (NASDAQ:PACB) Price Target Raised to $2.50
Pacific Biosciences of California (NASDAQ:PACB – Free Report) had its price target increased by Piper Sandler from $2.00 to $2.50 in a report released on Monday,Benzinga reports. They currently have a...
Quantexa News
11/14
Piper Sandler Forecasts Strong Price Appreciation for Pacific Biosciences of California (NASDAQ:PACB) Stock
Pacific Biosciences of California ( NASDAQ:PACB – Free Report had its price objective raised by Piper Sandler from $2.00 to $2.50 in a research report sent to investors on Monday morning, Benzinga rep...
Quantexa News
11/14
Pacific Biosciences of California (NASDAQ:PACB) Raised to “Hold” at UBS Group
was upgraded by analysts at UBS Group to a “hold” rating in a research note issued to investors on Sunday, Zacks.com reports. Several other research firms also recently issued reports on PACB. Cantor...
Quantexa News
11/14
Pacific Biosciences of California (NASDAQ:PACB) Raised to Hold at UBS Group
UBS Group upgraded shares of Pacific Biosciences of California (NASDAQ:PACB – Free Report) to a hold rating in a report released on Sunday,Zacks.com reports. Other equities research analysts have als...
Quantexa News
11/14
Pacific Biosciences of California (NASDAQ:PACB) Upgraded at UBS Group
UBS Group upgraded shares of Pacific Biosciences of California ( NASDAQ:PACB – Free Report to a hold rating in a research report report published on Sunday, Zacks.com reports. Several other research...
Quantexa News
11/14
Pacific Biosciences of California (NASDAQ:PACB) Stock Rating Lowered by UBS Group
Pacific Biosciences of California (NASDAQ:PACB – Get Free Report) was downgraded by research analysts at UBS Group from a “buy” rating to a “neutral” rating in a research report issued to clients and...
Quantexa News
11/15
Pacific Biosciences of California (NASDAQ:PACB) Price Target Cut to $6.00 by Analysts at Scotiabank
Pacific Biosciences of California ( NASDAQ:PACB – Free Report had its price objective decreased by Scotiabank from $7.00 to $6.00 in a research note released on Monday morning, Benzinga reports. Scoti...
Quantexa News
11/15
Scotiabank Cuts Pacific Biosciences of California (NASDAQ:PACB) Price Target to $6.00
Pacific Biosciences of California (NASDAQ:PACB – Free Report) had its price target reduced by Scotiabank from $7.00 to $6.00 in a research report released on Monday,Benzinga reports. They currently ha...
Quantexa News
11/15
Pacific Biosciences of California (NASDAQ:PACB) Stock Price Expected to Rise, Piper Sandler Analyst Says
Pacific Biosciences of California ( NASDAQ:PACB – Free Report had its target price boosted by Piper Sandler from $2.00 to $2.50 in a research report report published on Monday morning, Benzinga report...
Quantexa News
11/15
Piper Sandler Boosts Pacific Biosciences of California (NASDAQ:PACB) Price Target to $2.50
Pacific Biosciences of California ( NASDAQ:PACB – Free Report had its price objective lifted by Piper Sandler from $2.00 to $2.50 in a research report sent to investors on Monday, Benzinga reports. Pi...
Quantexa News
11/15
Pacific Biosciences of California (NASDAQ:PACB) Rating Lowered to “Neutral” at UBS Group
UBS Group downgraded shares of Pacific Biosciences of California ( NASDAQ:PACB – Free Report from a buy rating to a neutral rating in a report issued on Monday, MarketBeat.com reports. They currently...
Quantexa News
11/16
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Receives Consensus Recommendation of “Hold” from Analysts
Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Get Free Report ) has received an average recommendation of “Hold” from the fifteen analysts that are covering the firm, Marketbeat reports. Eig...
Quantexa News
11/16
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Given Consensus Rating of “Hold” by Brokerages
Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Get Free Report ) has received an average recommendation of “Hold” from the fifteen research firms that are currently covering the stock, Market...
Quantexa News
11/16
Pacific Biosciences of California (NASDAQ:PACB) Raised to Sell at StockNews.com
StockNews.com upgraded shares of Pacific Biosciences of California ( NASDAQ:PACB – Free Report to a sell rating in a research note issued to investors on Tuesday. Several other analysts have also com...
Quantexa News
11/16
Pacific Biosciences of California (NASDAQ:PACB) Upgraded by StockNews.com to Sell Rating
StockNews.com upgraded shares of Pacific Biosciences of California (NASDAQ:PACB – Free Report) to a sell rating in a research report released on Tuesday. PACB has been the topic of several other rese...
Quantexa News
11/18
Sumitomo Mitsui Trust Group Inc. Cuts Stock Holdings in Pacific Biosciences of California, Inc. (NASDAQ:PACB)
Sumitomo Mitsui Trust Group Inc. lessened its holdings in Pacific Biosciences of California, Inc. (NASDAQ:PACB – Free Report) by 6.1% during the 3rd quarter, according to its most recent disclosure wi...
Quantexa News
11/18
Sumitomo Mitsui Trust Group Inc. Reduces Holdings in Pacific Biosciences of California, Inc. (NASDAQ:PACB)
Sumitomo Mitsui Trust Group Inc. lowered its stake in shares of Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Free Report ) by 6.1% during the third quarter, according to its most recent For...
Quantexa News
11/18
Pacific Biosciences of California Inc (PACB) Stock: A Closer Look at the Analyst Ratings
Additionally, the 36-month beta value for PACB is 1.96. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 2 rating it as “overweight,” 8 rating it as “hold,” and 0 rating it...
Quantexa News
11/19
FY2024 EPS Estimates for PACB Reduced by Cantor Fitzgerald
Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Free Report ) – Equities researchers at Cantor Fitzgerald decreased their FY2024 earnings estimates for Pacific Biosciences of California in a r...
Quantexa News
11/19
Pacific Biosciences of California Inc (PACB) posted a -36.18% change over the last five days signaling a new trend
On Monday, Pacific Biosciences of California Inc (NASDAQ: PACB) opened lower -1.57% from the last session, before settling in for the closing price of $1.60. Price fluctuations for PACB have ranged fr...
Yahoo Finance News
11/19
Pacific Biosciences of California, Inc. (PACB): Among the Best Genomics Stocks to Buy Right Now
Pacific Biosciences of California, Inc. (PACB): Among the Best Genomics Stocks to Buy Right Now Fatima Gulzar Tue, Nov 19, 2024, 7:01 PM 6 min read In This Article: PACB +4.94% We recently compiled a...
Quantexa News
11/19
Pacific Biosciences of California, Inc. (PACB): Among the Best Genomics Stocks to Buy Right Now
We recently compiled a list of the 10 Best Genomics Stocks To Buy Right Now In this article, we are going to take a look at where Pacific Biosciences of California, Inc. (NASDAQ:PACB) stands against t...
Yahoo Finance Community
11/20
Comment
Pacbio’s technology of DNA sequencing is one of the most prominent at present and has potential to further costs cuts. The closest competitor is nanopope tech but that one is at earlier stages. The obvious problem is that even the best tech has yet to prove it can create value for shareholders 🤓...
Votes:
1
1
Quantexa News
11/21
Pacific Biosciences of California Inc (NASDAQ: PACB)'s -13.13% Loss This Week Just Tells Us Something New
During the last session, Pacific Biosciences of California Inc (NASDAQ:PACB)'s traded shares were 8.22 million, with the beta value of the company hitting 1.96. The 52-week high for the PACB share is...
Quantexa News
11/22
Pacific Biosciences of California : Material Agreement Form 8 K
Item 1.01 Entry Into a Material Definitive Agreement. On November 21, 2024, Pacific Biosciences of California, Inc. (the "Company") consummated (the "Closing") the previously announced privately nego...
Quantexa News
11/24
Senvest Management LLC Has $1.86 Million Holdings in Pacific Biosciences of California, Inc. (NASDAQ:PACB)
Senvest Management LLC grew its position in shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB – Free Report) by 36.1% in the 3rd quarter, according to the company in its most recent Form...
Quantexa News
11/25
Examining the Volatility of Pacific Biosciences of California Inc's (PACB) Stock
The stock of Pacific Biosciences of California Inc (PACB) has gone up by 12.85% for the week, with a 4.65% rise in the past month and a 12.50% rise in the past quarter. The volatility ratio for the we...
Quantexa News
11/25
Atria Investments Inc Acquires 10,138 Shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB)
Atria Investments Inc increased its holdings in shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB – Free Report) by 85.7% during the third quarter, according to the company in its most re...
Quantexa News
11/25
Pacific Biosciences of California (PACB) – Analysts’ Weekly Ratings Updates
Several analysts have recently updated their ratings and price targets for Pacific Biosciences of California (NASDAQ: PACB): 11/12/2024 – Pacific Biosciences of California was upgraded by analysts at...
Quantexa News
11/27
Principal Financial Group Inc. Sells 17,601 Shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB)
Principal Financial Group Inc. reduced its stake in shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB – Free Report) by 47.9% in the third quarter, according to its most recent filing wit...
Quantexa News
11/27
Principal Financial Group Inc. Sells 17,601 Shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB)
Principal Financial Group Inc. lessened its position in Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Free Report ) by 47.9% during the 3rd quarter, according to the company in its most rece...
Quantexa News
11/27
PacBio Unveils Vega Benchtop Sequencing Platform
PacBio has introduced the Vega system, a compact and affordable benchtop sequencing platform designed to expand access to its advanced HiFi long-read sequencing technology. Announced on November 4, 20...
Polygon News
11/28
Shrimp Hydrolysate Market Set to Surge to $675.9 Million with an Impressive 8.7% CAGR by 2034
The global shrimp hydrolysate market is projected to grow at 7% CAGR and reach US$ 675.9 million by 2034, driven by the growing need for sustainable and nutrient-rich animal feed, aquaculture commodit...
Quantexa News
11/29
Pacific Biosciences of California (NASDAQ:PACB) Trading 7.4% Higher – Time to Buy?
Pacific Biosciences of California, Inc. (NASDAQ:PACB – Get Free Report) rose 7.4% during trading on Friday . The stock traded as high as $1.90 and last traded at $1.89. Approximately 2,305,946 shares...
Quantexa News
11/30
Pacific Biosciences of California (NASDAQ:PACB) Trading 7.4% Higher - Time to Buy?
Pacific Biosciences of California, Inc. (NASDAQ:PACB - Get Free Report) rose 7.4% during trading on Friday . The stock traded as high as $1.90 and last traded at $1.89. Approximately 2,305,946 shares...
Quantexa News
12/01
Pacific Biosciences of California (NASDAQ:PACB) Trading Up 7.4% – Here's Why
Shares of Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Get Free Report ) shot up 7.4% during mid-day trading on Friday . The company traded as high as $1.90 and last traded at $1.89. 2,305,...
Quantexa News
12/01
Pacific Biosciences of California (NASDAQ:PACB) Stock Price Up 7.4% – Here’s Why
Pacific Biosciences of California, Inc. (NASDAQ:PACB – Get Free Report) shares were up 7.4% on Friday . The stock traded as high as $1.90 and last traded at $1.89. Approximately 2,305,946 shares chang...
Quantexa News
12/01
Algert Global LLC Trims Position in Pacific Biosciences of California, Inc. (NASDAQ:PACB)
Algert Global LLC reduced its holdings in Pacific Biosciences of California, Inc. (NASDAQ:PACB – Free Report) by 26.3% during the 3rd quarter, according to its most recent filing with the Securities a...
Quantexa News
12/03
Freedom Investment Management Inc. Cuts Stock Holdings in Pacific Biosciences of California, Inc. (NASDAQ:PACB)
Freedom Investment Management Inc. reduced its stake in Pacific Biosciences of California, Inc. (NASDAQ:PACB – Free Report) by 18.3% during the third quarter, according to its most recent filing with...
Quantexa News
12/03
Pacific Biosciences of California Inc (PACB) Shares Soar Above 1-Year High
Pacific Biosciences of California Inc (NASDAQ: PACB)'s stock price has increased by 1.05 compared to its previous closing price of 1.91. However, the company has seen a 7.22% increase in its stock pri...
Quantexa News
12/03
Pacific Biosciences of California Sees Unusually High Options Volume (NASDAQ:PACB)
Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Get Free Report ) was the target of some unusual options trading on Tuesday. Stock investors acquired 5,062 call options on the company. This re...
Quantexa News
12/04
Stock Traders Purchase Large Volume of Pacific Biosciences of California Call Options (NASDAQ:PACB)
Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Get Free Report ) was the recipient of unusually large options trading on Tuesday. Investors purchased 5,062 call options on the stock. This rep...
Quantexa News
12/04
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Given Average Rating of “Hold” by Analysts
Shares of Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Get Free Report ) have earned an average recommendation of “Hold” from the fifteen research firms that are presently covering the firm...
Quantexa News
12/04
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Given Average Rating of “Hold” by Analysts
NASDAQ:PACB – Get Free Report ) have earned a consensus rating of “Hold” from the fifteen analysts that are currently covering the company, MarketBeat.com reports. Eight analysts have rated the stock...
Quantexa News
12/05
Pacific Biosciences of California Target of Unusually Large Options Trading (NASDAQ:PACB)
Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Get Free Report ) saw some unusual options trading on Tuesday. Traders acquired 5,062 call options on the stock. This is an increase of 73% comp...
Quantexa News
12/05
Cathie Wood's Ark Invest Bets Big On Biotech Again As Pacific Biosciences Grabs Spotlight
Ark Invest CEO Cathie Wood is doubling down on genomics. What Happened: Pacific Biosciences of California Inc. (NASDAQ:PACB), known as PacBio, is biotech’s new kid on the block. The company's Vega se...
Quantexa News
12/06
17,605 Shares in Pacific Biosciences of California, Inc. (NASDAQ:PACB) Acquired by Atom Investors LP
Atom Investors LP acquired a new stake in Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Free Report ) in the 3rd quarter, Holdings Channel.com reports. The institutional investor acquired 17...
Quantexa News
12/06
Atom Investors LP Makes New Investment in Pacific Biosciences of California, Inc. (NASDAQ:PACB)
Atom Investors LP purchased a new stake in Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Free Report ) during the 3rd quarter, according to the company in its most recent disclosure with the...
Yahoo Finance Community
12/06
Comment
I am no market genius prognotisicator extraordinaire, BUT the motto of this stock has always been LOW RISK HIGH REWARD for me. It's hard to imagine this NOT becoming a $3 to $10 stock in a couple years..not sure where I'll set the buy mark again, but when it tanked off between 1.30 and change I scooped up a truckload...
Votes:
2
1
Yahoo Finance Community
12/06
Comment
The slide from $2.60 made little sense to anyone who knows anything about the prospects of the genomic revolution and PACB's position in it. A cohort of short sellers was misled by a shortsighted article published on SA. They drove the price in the opposite direction, down from $2.60, but the market is going to correct that very soon I'd say. Given the deal with SoftBank that secured PACB financially, this should be trading above $3. This price is a gift. Won't last forever....
Votes:
10
1
Quantexa News
12/07
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Receives $3.63 Consensus Price Target from Brokerages
Pacific Biosciences of California, Inc. (NASDAQ:PACB – Get Free Report) has been given an average rating of “Hold” by the fifteen brokerages that are presently covering the firm, MarketBeat reports. E...
Quantexa News
12/07
Brokerages Set Pacific Biosciences of California, Inc. (NASDAQ:PACB) Target Price at $3.63
Pacific Biosciences of California, Inc. (NASDAQ:PACB – Get Free Report) has been given an average recommendation of “Hold” by the fifteen ratings firms that are covering the firm, MarketBeat reports....
Quantexa News
12/07
Intech Investment Management LLC Purchases New Position in Pacific Biosciences of California, Inc. (NASDAQ:PACB)
Intech Investment Management LLC acquired a new position in shares of Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Free Report ) during the 3rd quarter, according to its most recent Form 13...
Quantexa News
12/08
Pacific Biosciences of California (NASDAQ:PACB) Shares Gap Up – Here's Why
Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Get Free Report )'s stock price gapped up prior to trading on Friday . The stock had previously closed at $1.98, but opened at $2.05. Pacific Bi...
Yahoo Finance Community
12/08
Comment
This is the way PACB could reach $6. Reaching a $6 price target for PACB would depend on several factors, including revenue growth, market sentiment, and the broader genomics sector performance. Analysts with a bullish view often cite the following key points: 1. Revenue Growth: Analysts project that PACB’s revenue could grow significantly from $159.7 million in 2024 to $194.9 million in 2025, and potentially beyond. Sustained growth at this rate could boost investor confidence and the stock price  . 2. Market Catalysts: The company needs breakthroughs in its core business, such as new product launches or expanded market adoption of its genomic sequencing technologies, which could drive demand and elevate its valuation. 3. Timeline: Assuming steady quarterly growth, it could realistically take 2–3 years for PACB to reach $6, depending on external factors such as competition and macroeconomic conditions. This aligns with analyst estimates projecting major upside over …...
Votes:
3
0
Quantexa News
12/09
Brokerages Set Pacific Biosciences of California, Inc. (NASDAQ:PACB) PT at $3.63
Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Get Free Report ) has been given an average recommendation of “Hold” by the fifteen research firms that are covering the stock, MarketBeat repor...
Quantexa News
12/09
MetLife Investment Management LLC Sells 33,996 Shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB)
MetLife Investment Management LLC lessened its position in shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB – Free Report) by 22.1% in the third quarter, according to the company in its...
Quantexa News
12/09
MetLife Investment Management LLC Sells 33,996 Shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB)
MetLife Investment Management LLC reduced its holdings in Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Free Report ) by 22.1% in the third quarter, HoldingsChannel reports. The firm owned 1...
Quantexa News
12/09
Now that Pacific Biosciences of California Inc's volume has hit 7.23 million, investors get a glimpse of its size.
Pacific Biosciences of California Inc (NASDAQ: PACB) kicked off on Friday, up 2.53% from the previous trading day, before settling in for the closing price of $1.98. Over the past 52 weeks, PACB has t...
Yahoo Finance Community
12/09
Comment
MD Anderson has opened a new department in response to patient requests. The Institute for Cell Therapy Discovery & Innovation. The article is available on their website. Search on the name. I’d post a link but I’ve gotten dinged for it in the past....
Votes:
2
0
Quantexa News
12/10
Pacific Biosciences of California Inc (NASDAQ: PACB) Stock: Can It Go Higher?
In the last trading session, 10.99 million shares of the Pacific Biosciences of California Inc (NASDAQ:PACB) were traded, and its beta was 1.95. Most recently the company's share price was $2.18, and...
Quantexa News
12/10
Pacific Biosciences of California (NASDAQ:PACB) Stock Price Up 5% – What's Next?
Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Get Free Report )'s share price shot up 5% during mid-day trading on Tuesday . The stock traded as high as $2.33 and last traded at $2.29. 3,754...
Quantexa News
12/11
BNP Paribas Financial Markets Has $1.13 Million Stake in Pacific Biosciences of California, Inc. (NASDAQ:PACB)
BNP Paribas Financial Markets lowered its position in Pacific Biosciences of California, Inc. (NASDAQ:PACB – Free Report) by 34.0% during the third quarter, according to its most recent filing with th...
Quantexa News
12/11
Benjamin Edwards Inc. Has $210,000 Holdings in Pacific Biosciences of California, Inc. (NASDAQ:PACB)
Benjamin Edwards Inc. raised its position in Pacific Biosciences of California, Inc. (NASDAQ:PACB – Free Report) by 12,341.8% during the third quarter, according to its most recent filing with the SEC...
Quantexa News
12/11
Benjamin Edwards Inc. Has $210,000 Holdings in Pacific Biosciences of California, Inc. (NASDAQ:PACB)
Benjamin Edwards Inc. boosted its holdings in Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Free Report ) by 12,341.8% in the 3rd quarter, according to its most recent filing with the Securi...
Quantexa News
12/11
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Given Average Rating of “Hold” by Brokerages
Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Get Free Report ) has received a consensus recommendation of “Hold” from the fifteen ratings firms that are currently covering the stock, Market...
Quantexa News
12/11
Why Pacific Biosciences of California (PACB) Is the Worst ARK Stock to Buy According to Short Sellers
We recently published a list of 10 Worst ARK Stocks To Buy According to Short Sellers. In this article, we are going to take a look at where Pacific Biosciences of California, Inc. (NASDAQ:PACB) stand...
Quantexa News
12/11
Pacific Biosciences of California (NASDAQ:PACB) Stock Price Down 6.4% – Here's What Happened
Pacific Biosciences of California, Inc. ( – )'s stock price traded down 6.4% on Wednesday . The company traded as low as $2.18 and last traded at $2.19. 2,256,368 shares traded hands during trading, a...
Quantexa News
12/12
Pacific Biosciences of California (NASDAQ:PACB) Trading 5% Higher – Still a Buy?
Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Get Free Report ) shares shot up 5% during trading on Tuesday . The stock traded as high as $2.33 and last traded at $2.29. 3,754,297 shares cha...
Quantexa News
12/12
Reasons to Retain PacBio Stock in Your Portfolio for Now
Pacific Biosciences of California, Inc. PACB, popularly known as PacBio, has been gaining from its continued focus on research and development. The optimism, led by decent second-quarter 2024 earnings...
Yahoo Finance Community
12/13
Comment
Typically add at $1.80 and lower....underwater a little today, finally got my average down to $2.01. Hope if this drops enough to get to below $2.00. Holding this long term and looking for fun down the road being persistent. Best to all longs....
Votes:
8
2
Quantexa News
12/13
Pacific Biosciences of California (NASDAQ:PACB) Stock Price Down 6.4% – Here's What Happened
Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Get Free Report )'s share price traded down 6.4% on Wednesday . The company traded as low as $2.18 and last traded at $2.19. 2,256,368 shares ch...
Quantexa News
12/13
Pacific Biosciences of California (NASDAQ:PACB) Stock Price Down 6.4% – Time to Sell?
Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Get Free Report )'s share price traded down 6.4% during mid-day trading on Wednesday . The company traded as low as $2.18 and last traded at $2....
Quantexa News
12/14
Centiva Capital LP Makes New $40,000 Investment in Pacific Biosciences of California, Inc. (NASDAQ:PACB)
Centiva Capital LP acquired a new stake in shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB – Free Report) during the 3rd quarter, according to the company in its most recent filing with...
Quantexa News
12/15
Charles Schwab Investment Management Inc. Acquires 82,807 Shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB)
Charles Schwab Investment Management Inc. boosted its holdings in Pacific Biosciences of California, Inc. (NASDAQ:PACB – Free Report) by 4.2% in the 3rd quarter, according to its most recent Form 13F...
Quantexa News
12/15
The Manufacturers Life Insurance Company Decreases Stake in Pacific Biosciences of California, Inc. (NASDAQ:PACB)
The Manufacturers Life Insurance Company lessened its stake in shares of Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Free Report ) by 10.4% during the 3rd quarter, Holdings Channel reports...
Quantexa News
12/15
The Manufacturers Life Insurance Company Reduces Holdings in Pacific Biosciences of California, Inc. (NASDAQ:PACB)
The Manufacturers Life Insurance Company lowered its position in Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Free Report ) by 10.4% during the 3rd quarter, according to the company in its...
Quantexa News
12/15
Arete Wealth Advisors LLC Sells 16,748 Shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB)
Arete Wealth Advisors LLC lowered its stake in Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Free Report ) by 20.2% during the third quarter, according to the company in its most recent Form...
Quantexa News
12/15
Arete Wealth Advisors LLC Sells 16,748 Shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB)
Arete Wealth Advisors LLC lowered its stake in Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Free Report ) by 20.2% during the third quarter, according to its most recent Form 13F filing wit...
Quantexa News
12/16
Pacific Biosciences of California Inc (PACB): A Technical Analysis
PACB has 36-month beta value of 1.95. Analysts have mixed views on the stock, with 6 analysts rating it as a “buy,” 1 as “overweight,” 8 as “hold,” and 0 as “sell.” The public float for PACB is 241.8...
Quantexa News
12/16
Cathie Wood's ARK Investment buys 274.9K shares of PacBio today
20:05 EST Cathie Wood's ARK Investment buys 274.9K shares of PacBio ( PACB ) today Pick the best stocks and maximize your portfolio: Discover top-rated stocks from highly ranked analysts with Analys...
Quantexa News
12/18
Cathie Wood's ARK Investment buys 341K shares of PacBio today
20:11 EST Cathie Wood's ARK Investment buys 341K shares of PacBio ( PACB ) today Pick the best stocks and maximize your portfolio: Discover top-rated stocks from highly ranked analysts with Analyst...
Quantexa News
12/18
Fmr LLC Raises Stock Position in Pacific Biosciences of California, Inc. (NASDAQ:PACB)
Fmr LLC increased its holdings in Pacific Biosciences of California, Inc. (NASDAQ:PACB – Free Report) by 641.3% during the third quarter, according to its most recent disclosure with the SEC. The inst...
Quantexa News
12/18
Fmr LLC Raises Stake in Pacific Biosciences of California, Inc. (NASDAQ:PACB)
Fmr LLC boosted its holdings in Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Free Report ) by 641.3% during the third quarter, according to the company in its most recent disclosure with th...
Yahoo Finance Community
12/19
Comment
Interviewer: is this the time to invest in your company? is it undervalued?COH: it's not for me to determine our value, i just run the company and throw parties.Interviewer: ok, then, you are worth somewhere less than $2/shareCOH: ok, you guys determine the value. i'll focus on making things great for researchers and make their boring lives interesting....
Quantexa News
12/20
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Stock Position Reduced by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC decreased its stake in Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Free Report ) by 14.2% in the third quarter, Holding...
Yahoo Finance Community
12/20
Comment
Foolish bears...this company is in a decent position in an industry that is literally bleeding to death. 95% of bears are speaking in general to the industry but are directing the hate to PACB. I understand but literally everything your saying could be applied to every geno company in market. Get out of your emotion and continue to hold or just sell off and let CATHIE buy your shares....
Votes:
3
0
Quantexa News
12/20
China Neurogenomics Market Research 2024-2031, Profiles of Illumina, Thermo Fisher Scientific, F. Hoffmann-La Roche, MGI Tech, Agilent, Revvity, Qiagen, Pacific Biosciences, Danaher, Oxford Nanopore - ResearchAndMarkets.com
December 20, 2024 at 11:15 AM EST The "China Neurogenomics Market Size, Share, Forecast, & Trends Analysis by Offering, PCR, Microarrays, Application, End User - Forecast to 2031" report has been add...
Quantexa News
12/20
China Neurogenomics Market Research 2024-2031, Profiles of Illumina, Thermo Fisher Scientific, F. Hoffmann-La Roche, MGI Tech, Agilent, Revvity, Qiagen, Pacific Biosciences, Danaher, Oxford Nanopore - ResearchAndMarkets.com
DUBLIN --(BUSINESS WIRE) The "China Neurogenomics Market Size, Share, Forecast, & Trends Analysis by Offering, PCR, Microarrays, Application, End User - Forecast to 2031" report has been added to Res...
Quantexa News
12/20
Pacific Biosciences of California Inc (NASDAQ:PACB) Could Really Rise To 4 In 12 Months, According To Analysts.
In recent trading session, Pacific Biosciences of California Inc (NASDAQ:PACB) saw 2.3 million shares changing hands at last check today with its beta currently measuring 1.93. Company's recent per sh...
Quantexa News
12/21
Virtu Financial LLC Sells 35,242 Shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB)
Virtu Financial LLC cut its holdings in shares of Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Free Report ) by 55.9% in the 3rd quarter, according to the company in its most recent disclos...
Quantexa News
12/21
Virtu Financial LLC Reduces Stock Position in Pacific Biosciences of California, Inc. (NASDAQ:PACB)
Virtu Financial LLC trimmed its holdings in Pacific Biosciences of California, Inc. (NASDAQ:PACB – Free Report) by 55.9% in the third quarter, according to its most recent 13F filing with the Securiti...
Quantexa News
12/23
An Overview of Pacific Biosciences of California Inc (NASDAQ: PACB)'s Stock Performance and Outlook
In the latest trading session, 1.41 million Pacific Biosciences of California Inc (NASDAQ:PACB) shares changed hands as the company's beta touched 1.94. With the company's most recent per share price...
Quantexa News
12/26
Tidal Investments LLC Has $36,000 Position in Pacific Biosciences of California, Inc. (NASDAQ:PACB)
Tidal Investments LLC decreased its position in shares of Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Free Report ) by 78.7% during the 3rd quarter, according to the company in its most re...
Quantexa News
12/26
Tidal Investments LLC Has $36,000 Stock Position in Pacific Biosciences of California, Inc. (NASDAQ:PACB)
Tidal Investments LLC lowered its stake in shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB – Free Report) by 78.7% during the third quarter, according to its most recent disclosure with...
Quantexa News
12/26
Pacific Biosciences of California Inc (NASDAQ: PACB) Gain Of 38.62% Compared To 52-Week Low; YTD Fall -80.73% – What Should You Do Now?
Pacific Biosciences of California Inc (NASDAQ:PACB)'s traded shares stood at 1.37 million during the latest session, with the company's beta value hitting 1.95. At the last check today, the stock's pr...
Quantexa News
12/27
HighTower Advisors LLC Sells 8,318 Shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB)
HighTower Advisors LLC cut its position in shares of Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Free Report ) by 33.4% during the 3rd quarter, according to its most recent disclosure with...
Quantexa News
12/27
HighTower Advisors LLC Sells 8,318 Shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB)
HighTower Advisors LLC lowered its stake in Pacific Biosciences of California, Inc. (NASDAQ:PACB – Free Report) by 33.4% in the 3rd quarter, according to the company in its most recent 13F filing with...
Quantexa News
12/27
State Street Corp Has $10.67 Million Stock Holdings in Pacific Biosciences of California, Inc. (NASDAQ:PACB)
State Street Corp grew its holdings in shares of Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Free Report ) by 5.7% in the third quarter, according to its most recent Form 13F filing with t...
Quantexa News
12/27
State Street Corp Boosts Position in Pacific Biosciences of California, Inc. (NASDAQ:PACB)
State Street Corp grew its stake in shares of Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Free Report ) by 5.7% during the 3rd quarter, HoldingsChannel reports. The institutional investor...
Quantexa News
12/28
Pacific Biosciences of California (NASDAQ:PACB) Shares Gap Down – Here's Why
Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Get Free Report )'s share price gapped down before the market opened on Thursday . The stock had previously closed at $1.95, but opened at $1.90...
Quantexa News
12/29
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Receives Average Recommendation of “Moderate Buy” from Analysts
Shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB – Get Free Report) have received an average rating of “Moderate Buy” from the twelve ratings firms that are presently covering the firm,...
Quantexa News
12/30
Pacific Biosciences of California Inc (PACB) volume exceeds 7.17 million: A new investment opportunity for investors
Pacific Biosciences of California Inc (NASDAQ: PACB) on Friday, plunged -3.63% from the previous trading day, before settling in for the closing price of $1.93. Within the past 52 weeks, PACB's price...
Quantexa News
12/30
Why Is Pacific Biosciences of California, Inc. (PACB) Among the Top CRISPR Stocks to Invest In?
We recently compiled a list of the In this article, we are going to take a look at where Pacific Biosciences of California, Inc. (NASDAQ:PACB) stands against the other CRISPR stocks. The pharmaceutic...
Quantexa News
12/30
Why Is Pacific Biosciences of California, Inc. (PACB) Among the Top CRISPR Stocks to Invest In?
We recently compiled a list of the Top 11 CRISPR Stocks to Invest In In this article, we are going to take a look at where Pacific Biosciences of California, Inc. (NASDAQ:PACB) stands against the othe...
Quantexa News
01/01
Analysts Set Pacific Biosciences of California, Inc. (NASDAQ:PACB) PT at $2.95
Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Get Free Report ) has received an average rating of “Moderate Buy” from the twelve research firms that are covering the firm, Marketbeat.com rep...
Quantexa News
01/01
Brokerages Set Pacific Biosciences of California, Inc. (NASDAQ:PACB) PT at $2.95
Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Get Free Report ) has been assigned an average recommendation of “Moderate Buy” from the twelve ratings firms that are covering the firm, Market...
Quantexa News
01/01
Geode Capital Management LLC Boosts Stock Position in Pacific Biosciences of California, Inc. (NASDAQ:PACB)
Geode Capital Management LLC increased its holdings in shares of Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Free Report ) by 3.7% during the third quarter, according to its most recent fi...
Quantexa News
01/01
Geode Capital Management LLC Boosts Holdings in Pacific Biosciences of California, Inc. (NASDAQ:PACB)
Geode Capital Management LLC grew its position in Pacific Biosciences of California, Inc. (NASDAQ:PACB – Free Report) by 3.7% during the 3rd quarter, according to its most recent Form 13F filing with...
Quantexa News
01/02
177,936 Shares in Pacific Biosciences of California, Inc. (NASDAQ:PACB) Bought by Franklin Resources Inc.
Franklin Resources Inc. purchased a new stake in Pacific Biosciences of California, Inc. (NASDAQ:PACB – Free Report) during the third quarter, according to its most recent 13F filing with the Securiti...
Quantexa News
01/02
Franklin Resources Inc. Invests $302,000 in Pacific Biosciences of California, Inc. (NASDAQ:PACB)
Franklin Resources Inc. bought a new stake in shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB – Free Report) in the 3rd quarter, HoldingsChannel.com reports. The institutional investor...
Yahoo Finance Community
01/02
Comment
Anything under $2 is a great buy….based on past statements, company is positioned to be profitable by end of year. If one is to wait until that happens it will be too late as the markets can predict the near future sentiment and will adjust accordingly without you even realizing it....
Votes:
4
1
Quantexa News
01/03
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Receives Average Rating of “Moderate Buy” from Brokerages
Shares of Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Get Free Report ) have earned an average recommendation of “Moderate Buy” from the twelve research firms that are presently covering t...
Quantexa News
01/03
Analysts Set Pacific Biosciences of California, Inc. (NASDAQ:PACB) Target Price at $2.95
NASDAQ:PACB – Get Free Report ) have been given an average rating of “Moderate Buy” by the twelve analysts that are presently covering the company, Marketbeat reports. Six investment analysts have rat...
Quantexa News
01/03
Pacific Biosciences of California Target of Unusually Large Options Trading (NASDAQ:PACB)
Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Get Free Report ) was the target of unusually large options trading activity on Friday. Stock traders bought 10,843 call options on the stock. T...
Quantexa News
01/03
Traders Purchase Large Volume of Call Options on Pacific Biosciences of California (NASDAQ:PACB)
Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Get Free Report ) saw some unusual options trading on Friday. Stock traders purchased 10,843 call options on the company. This represents an inc...
Quantexa News
01/03
Pacific Biosciences of California (NASDAQ:PACB) Trading 7.2% Higher – Here's What Happened
NASDAQ:PACB – Get Free Report ) rose 7.2% on Friday . The stock traded as high as $1.95 and last traded at $1.93. Approximately 2,157,941 shares traded hands during mid-day trading, a decline of 37% f...
Quantexa News
01/04
Pacific Biosciences of California Sees Unusually Large Options Volume (NASDAQ:PACB)
Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Get Free Report ) saw some unusual options trading on Friday. Investors acquired 10,843 call options on the stock. This represents an increase o...
Quantexa News
01/04
Stock Traders Purchase High Volume of Call Options on Pacific Biosciences of California (NASDAQ:PACB)
Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Get Free Report ) was the recipient of some unusual options trading activity on Friday. Stock traders acquired 10,843 call options on the stock....
Quantexa News
01/05
Pacific Biosciences of California Sees Unusually High Options Volume (NASDAQ:PACB)
Pacific Biosciences of California, Inc. (NASDAQ:PACB – Get Free Report) was the recipient of unusually large options trading on Friday. Stock traders acquired 10,843 call options on the company. This...
Quantexa News
01/05
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Receives $2.95 Consensus Target Price from Analysts
Shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the twelve brokerages that are presently covering...
Quantexa News
01/05
Pacific Biosciences of California (NASDAQ:PACB) Shares Up 7.2% – Time to Buy?
Shares of Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Get Free Report ) shot up 7.2% during mid-day trading on Friday . The stock traded as high as $1.95 and last traded at $1.93. 2,157,94...
Quantexa News
01/05
PacBio Unveils the Vega System, a New Sequencing Platform Bringing HiFi to the Benchtop
Priced at just $169,000 Vega is designed to make highly accurate long-read sequencing accessible to any laboratory PacBio, developer of the world’s most advanced sequencing technologies, has announced...
Quantexa News
01/06
Understanding the Recent Fluctuations of Pacific Biosciences of California Inc's (PACB) Stock
In the past week, PACB stock has gone up by 3.11%, with a monthly gain of 8.74% and a quarterly surge of 22.09%. The volatility ratio for the week is 7.20%, and the volatility levels for the last 30 d...
Quantexa News
01/06
Cathie Wood's ARK Investment bought 397K shares of PacBio today
20:07 EST Cathie Wood's ARK Investment bought 397K shares of PacBio ( PACB ) today Don't Miss Our New Year's Offers: Discover the latest stocks recommended by top Wall Street analysts, all in one pl...
Quantexa News
01/07
Analysts' Top Healthcare Picks: RxSight (RXST), Pacific Biosciences (PACB)
There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on RxSight ( RXST – Research Report ) and Pacific Biosciences ( PACB – Research Report ) with bullish sentim...
Yahoo Finance Community
01/07
Comment
temptations with this penny stock. So tempted to sell this morning and chase high flyers, but then realized that this might be a "safer" penny stock to hold large positions over months at a time. You chase three day flyers with zero revenue and don't know which day or which hour the position can reverse on you.PB as a penny stock is looking good for large position holders! I bought more yesterday at 2.02 down to 1.96, then market makers promptly started selling it down to cover their short to me. I believe i was the market participant that helped create that dump to 1.90....but looking great today!...
Quantexa News
01/08
Principal Financial Group Inc. Decreases Position in Pacific Biosciences of California, Inc. (NASDAQ:PACB)
Principal Financial Group Inc. decreased its position in Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Free Report ) by 47.9% during the 3rd quarter, according to the company in its most rec...
Yahoo Finance News
01/08
PacBio Announces Shipment of Vega Systems to Berry Genomics to Support its Clinical Assay Development for Asian Markets
PacBio Announces Shipment of Vega Systems to Berry Genomics to Support its Clinical Assay Development for Asian Markets PacBio Wed, Jan 8, 2025, 9:05 AM 5 min read In This Article: PACB +5.00% PacBio...
Quantexa News
01/09
Pacific Biosciences of California (NASDAQ:PACB) Stock Rating Upgraded by StockNews.com
Pacific Biosciences of California ( NASDAQ:PACB – Get Free Report was upgraded by StockNews.com to a “sell” rating in a research note issued to investors on Thursday. A number of other equities analy...
Quantexa News
01/09
Pacific Biosciences of California (NASDAQ:PACB) Upgraded to Sell at StockNews.com
Pacific Biosciences of California ( NASDAQ:PACB – Get Free Report was upgraded by equities researchers at StockNews.com to a “sell” rating in a report released on Thursday. A number of other analysts...
Quantexa News
01/10
Pacific Biosciences of California (NASDAQ:PACB) Rating Increased to Sell at StockNews.com
StockNews.com upgraded shares of Pacific Biosciences of California ( NASDAQ:PACB – Free Report to a sell rating in a report issued on Thursday morning. Several other equities research analysts have a...
Quantexa News
01/10
Pacific Biosciences of California (NASDAQ:PACB) Upgraded by StockNews.com to Sell Rating
StockNews.com upgraded shares of Pacific Biosciences of California (NASDAQ:PACB – Free Report) to a sell rating in a research report report published on Thursday morning. Other equities research anal...
Quantexa News
01/10
PacBio and Intus Bio Collaborate for Launch of GutID, First At-Home Microbi
MENLO PARK, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, and Intus Bio, a leader in microbiome research and discover...
Quantexa News
01/10
PacBio and Intus Bio Collaborate for Launch of GutID, First At-Home Microbiome Test Powered by HiFi Sequencing
MENLO PARK, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, and Intus Bio, a leader in microbiome research and discover...
Quantexa News
01/10
PacBio and Intus Bio Collaborate for Launch of GutID, First At-Home Microbiome Test Powered by HiFi Sequencing
MENLO PARK, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, and Intus Bio, a leader in microbiome research and discover...
Quantexa News
01/10
PacBio and Intus Bio Collaborate for Launch of GutID, First At-Home Microbiome Test Powered by HiFi Sequencing
January 10, 2025 at 06:05 am EST MENLO PARK, Calif. Jan. 10, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, and Intus Bio, a leader in...
Reddit
01/10
$PACB, update on PACB. The stock is up 8% and looking to make bigger move.
The company just came up with new PR which is listed below: PacBio (NASDAQ:PACB), developer of the world's most advanced sequencing technologies, and Intus Bio, a leader in microbiome research and d...
Reddit
01/10
$PACB, update on PACB. The stock is up 8% and looking to make bigger move.
The company just came up with new PR which is listed below: PacBio (NASDAQ:PACB), developer of the world's most advanced sequencing technologies, and Intus Bio, a leader in microbiome research and d...
Quantexa News
01/10
PacBio and Intus Bio Collaborate for Launch of GutID, First At-Home Microbiome Test Powered by HiFi Sequencing
MENLO PARK, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, and Intus Bio, a leader in microbiome research and discover...
Quantexa News
01/10
Pacbio And Intus Bio Collaborate For Launch Of Gutid, First At-Home Microbiome Test Powered By Hifi Sequencing
MENAFN - GlobeNewsWire - Nasdaq) MENLO PARK, Calif., Jan. 10, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), developer of the world's most advanced sequencing technologies, and Intus Bio, a leader in...
Yahoo Finance News
01/10
PACB Stock Rises After the Shipment of Vega Systems to Berry Genomics
PACB Stock Rises After the Shipment of Vega Systems to Berry Genomics Zacks Equity Research Fri, Jan 10, 2025, 7:14 AM 4 min read In This Article: PACB 0.00% Pacific Biosciences of California, Inc. PA...
Quantexa News
01/10
Bernstein Sticks to Its Buy Rating for Pacific Biosciences (PACB)
Bernstein analyst Eve Burstein maintained a Buy rating on Pacific Biosciences ( PACB – Research Report ) today and set a price target of $3.00. The company's shares closed last Wednesday at $2.10. S...
Quantexa News
01/11
Pacific Biosciences of California (NASDAQ:PACB) Stock Rating Upgraded by StockNews.com
Pacific Biosciences of California (NASDAQ:PACB – Get Free Report) was upgraded by equities research analysts at StockNews.com to a “sell” rating in a research note issued to investors on Thursday. Ge...
Quantexa News
01/11
StockNews.com Upgrades Pacific Biosciences of California (NASDAQ:PACB) to “Sell”
Pacific Biosciences of California ( NASDAQ:PACB – Get Free Report was upgraded by equities researchers at StockNews.com to a “sell” rating in a research note issued on Thursday. Other analysts have a...
Quantexa News
01/12
Pacific Biosciences of California (NASDAQ:PACB) Raised to “Sell” at StockNews.com
StockNews.com upgraded shares of Pacific Biosciences of California (NASDAQ:PACB – Free Report) to a sell rating in a report released on Thursday. A number of other equities research analysts have als...
Quantexa News
01/13
Nordea Investment Management AB Has $915,000 Holdings in Pacific Biosciences of California, Inc. (NASDAQ:PACB)
Nordea Investment Management AB lifted its stake in shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB – Free Report) by 21.5% in the 4th quarter, according to the company in its most rece...
Quantexa News
01/13
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Insider Sells $69,842.15 in Stock
Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Get Free Report ) insider Oene Mark Van sold 34,405 shares of the business's stock in a transaction on Friday, January 10th. The shares were sol...
Quantexa News
01/13
Insider Selling: Pacific Biosciences of California, Inc. (NASDAQ:PACB) Insider Sells $69,842.15 in Stock
Pacific Biosciences of California, Inc. (NASDAQ:PACB – Get Free Report) insider Oene Mark Van sold 34,405 shares of the company’s stock in a transaction that occurred on Friday, January 10th. The stoc...
Quantexa News
01/13
Analysts Conflicted on These Healthcare Names: Pacific Biosciences (PACB) and Pharvaris (PHVS)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Pacific Biosciences ( PACB – Research Report ) and Pharvaris ( PHVS – Research Report Stay Ahead of the Market: Dis...
Quantexa News
01/13
Pacific Biosciences (PACB) Receives a Hold from Morgan Stanley
In a report released today, Tejas Savant from Morgan Stanley maintained a Hold rating on Pacific Biosciences ( PACB – Research Report ), with a price target of . The company's shares closed last Frida...
Quantexa News
01/14
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Position Boosted by Green Alpha Advisors LLC
Green Alpha Advisors LLC raised its holdings in shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB – Free Report) by 59.5% during the 4th quarter, according to its most recent 13F filing w...
Quantexa News
01/14
PCA Investment Advisory Services Inc. Boosts Stake in Pacific Biosciences of California, Inc. (NASDAQ:PACB)
NASDAQ:PACB – Free Report ) by 50.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 15,000 shares of the biot...
Quantexa News
01/14
PacBio Announces Preliminary Fourth Quarter and Full Year Revenue
Commenced shipment of the Vega ™ benchtop system ahead of schedule, bringing HiFi sequencing to more customers Launched SPRQ chemistry, enabling the sub-$500 HiFi genome on the Revio ® system MENLO...
Quantexa News
01/14
PacBio Announces Preliminary Fourth Quarter and Full Year Revenue
Commenced shipment of the Vega ™ benchtop system ahead of schedule, bringing HiFi sequencing to more customers Launched SPRQ chemistry, enabling the sub-$500 HiFi genome on the Revio ® system MENLO...
Quantexa News
01/14
Pacific Biosciences of California (NASDAQ:PACB) Shares Gap Down – Should You Sell?
Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Get Free Report ) gapped down before the market opened on Tuesday . The stock had previously closed at $2.01, but opened at $1.93. Pacific Biosc...
Quantexa News
01/14
Pacific Biosciences of California (NASDAQ:PACB) Shares Gap Down – Should You Sell?
NASDAQ:PACB – Get Free Report ) shares gapped down prior to trading on Tuesday . The stock had previously closed at $2.01, but opened at $1.93. Pacific Biosciences of California shares last traded at...
Quantexa News
01/14
Pacific Bio (PACB) Announces Preliminary Fourth Quarter and Full Year Revenue
PacBio (NASDAQ: PACB ), a leading developer of high-quality, highly accurate sequencing solutions, announced preliminary unaudited revenue for the fourth quarter of 2024 and full year 2024 of $39.2 mi...
Quantexa News
01/14
PacBio reports Q4 preliminary revenue $39.2M, consensus $40.63M
The company also announced preliminary unaudited revenue for the full year 2024 of $154M. “Though challenging, 2024 was a productive year for PacBio ( PACB ) as we launched groundbreaking products, st...
Yahoo Finance Community
01/14
Comment
395 institutional owners and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 294,498,309 shares.I too am becoming an institution. Best of luck and success to anyone waiting....
Votes:
4
0
Polygon News
01/15
Neurogenomics Market Forecast and Trends Analysis to 2031: Healthcare Investments and Early Detection Drive Robust Uptake of Neurogenomics Solutions
The neurogenomics market is projected to reach $4.68 billion by 2031, driven by declining sequencing costs, increasing prevalence of neurological disorders, and advancements in sequencing technologies...
Quantexa News
01/15
Neurogenomics Market Forecast and Trends Analysis to 2031: Healthcare Investments and Early Detection Drive Robust Uptake of Neurogenomics Solutions
GlobeNewswire The report profiles leading players in the Neurogenomics market including Illumina, Thermo Fisher Scientific, F. Hoffmann-La Roche, Agilent Technologies, MGI Tech Co., QIAGEN, Revvity,...
Quantexa News
01/15
Neurogenomics Market Forecast and Trends Analysis to 2031: Healthcare Investments and Early Detection Drive Robust Uptake of Neurogenomics Solutions
Company Logo The report profiles leading players in the Neurogenomics market including Illumina, Thermo Fisher Scientific, F. Hoffmann-La Roche, Agilent Technologies, MGI Tech Co., QIAGEN, Revvity, P...
Yahoo Finance News
01/15
PACB Stock Falls on Preliminary Q4 Sales Miss, 7 Vega Systems Shipped
PACB Stock Falls on Preliminary Q4 Sales Miss, 7 Vega Systems Shipped Zacks Equity Research Wed, Jan 15, 2025, 5:57 AM 4 min read In This Article: PACB -7.09% ABT +1.94% Pacific Biosciences of Califor...
Quantexa News
01/15
Barclays Reaffirms Their Hold Rating on Pacific Biosciences (PACB)
In a report released today, Luke Sergott from Barclays maintained a Hold rating on Pacific Biosciences ( PACB – Research Report ), with a price target of . The company's shares closed yesterday at $1....
Quantexa News
01/16
FNY Investment Advisers LLC Invests $45,000 in Pacific Biosciences of California, Inc. (NASDAQ:PACB)
FNY Investment Advisers LLC bought a new stake in Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Free Report ) in the 4th quarter, according to its most recent disclosure with the Securities...
Yahoo Finance Community
01/16
Comment
we will likely see $1.50s before bounce up to $1.90s. The most predictable stock ever! : 1.75, at support, 1.58 ± 0.167 type triple+, strength 10Support Below : -28% at 1.26 ± 0.134 type single, strength 3Resistance Above : +15.8% at 2.03 ± 0.215 type triple+, strength 10...
Votes:
1
1
Quantexa News
01/16
Pacific Biosciences of California (NASDAQ:PACB) Shares Gap Down – Should You Sell?
Pacific Biosciences of California, Inc. (NASDAQ:PACB – Get Free Report) shares gapped down prior to trading on Tuesday . The stock had previously closed at $2.01, but opened at $1.93. Pacific Bioscien...
Yahoo Finance Community
01/16
Comment
Terrible price action….analyst keep reintegrating buy and hold…do you really thinking anyone other than retails will exit there position at ATL and revenue at almost ATH? However I do believe it’s time for Christian Henry to go. As a CEO you have to be a salesman and a good one. He doesn’t give the investors hope in the product other than fact that we all know geno will be big in the future. He has to go before we turn around...
Votes:
1
1
Quantexa News
01/16
Pacific Biosciences of California (NASDAQ:PACB) Shares Gap Down – Should You Sell?
Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Get Free Report ) shares gapped down prior to trading on Tuesday . The stock had previously closed at $2.01, but opened at $1.93. Pacific Biosci...
Yahoo Finance Community
01/16
Comment
Some of you complain that the CEO isn't a good salesman, but the customers of PacBio are no ordinary customers. They need scientific facts, that PacBio's systems are helpful in scientific discovery and that is why he pointed out the 1000+ papers that referenced them in the last conference....
Votes:
5
0
Yahoo Finance Community
01/16
Comment
There are only so many sequencing machines you can sell per quarter. This company needs another line of business to supplement the falling revenue. May be they could convert a few labs into contract GLP compliant sequencing service similar to Eurofin, GMP manufacture mol biol reagents for other companies that do not have cGMP compliant facility, servicing cell and gene therapy ..etc etc. Ofcourse they will need new money which means new debt or selling shares. Present is not sustainable :(...
Quantexa News
01/16
Bernstein Sticks to Its Buy Rating for Pacific Biosciences (PACB)
In a report released today, Eve Burstein from Bernstein maintained a Buy rating on Pacific Biosciences ( PACB – Research Report ), with a price target of . The company's shares closed yesterday at $1....
Quantexa News
01/20
Avanza Fonder AB Acquires New Holdings in Pacific Biosciences of California, Inc. (NASDAQ:PACB)
Avanza Fonder AB bought a new position in shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB – Free Report) in the fourth quarter, HoldingsChannel.com reports. The firm bought 76,408 share...
Polygon News
01/20
RNA Transcriptome Profiling Tests Market Expands at 14.5% CAGR, Surpassing US$ 37 Billion by 2034 | Fact.MR Report
The global RNA transcriptome profiling test market is expected to grow at a CAGR of 14.5% and reach a valuation of US$ 37,383.8 million by 2034, driven by increasing investments in biotechnology and g...
Quantexa News
01/21
Balance Sheet Breakdown: Pacific Biosciences of California Inc (PACB)'s Debt-to-Equity and Long-Term Debt/Eq Ratios
In the quest to outshine the broader market, stock pickers diligently seek out stocks with the potential for superior performance. Making the right choices can significantly elevate your wealth. Aft...
Quantexa News
01/21
The -11.59% Simple Moving Average of Pacific Biosciences of California Inc's (PACB) Stock in the Past 200 Days
The stock of Pacific Biosciences of California Inc (PACB) has seen a -21.90% decrease in the past week, with a -20.00% drop in the past month, and a -20.39% decrease in the past quarter. The volatilit...
Quantexa News
01/21
Pacific Biosciences of California Inc (NASDAQ: PACB): A Competitive Analysis And Growth Prospects
In today's recent session, 1.47 million shares of the Pacific Biosciences of California Inc (NASDAQ:PACB) have been traded, and its beta is 1.93. Most recently the company's share price was $1.67, and...
Quantexa News
01/22
Bourne Lent Asset Management Inc. Cuts Stock Position in Pacific Biosciences of California, Inc. (NASDAQ:PACB)
Bourne Lent Asset Management Inc. lessened its stake in Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Free Report ) by 1.1% during the 4th quarter, according to its most recent disclosure wi...
Quantexa News
01/22
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Shares Sold by Bourne Lent Asset Management Inc.
Bourne Lent Asset Management Inc. decreased its position in shares of Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Free Report ) by 1.1% during the 4th quarter, Holdings Channel.com reports...
Yahoo Finance News
01/22
Here's Why You Should Retain PacBio Stock in Your Portfolio for Now
Here's Why You Should Retain PacBio Stock in Your Portfolio for Now Zacks Equity Research Wed, Jan 22, 2025, 8:30 AM 5 min read In This Article: PACB -9.67% ABT +4.19% Pacific Biosciences of Californi...
Yahoo Finance Community
01/22
Comment
Check the news about Stargate. This stock is going to the moon. The project's first data centers are already under construction in Texas. In total, 20 data centers will be built at half a million square feet each. The project will power artificial intelligence that processes electronic health records. In order to fill those 20 data centers with data the project will need outputs from long-read sequencing. This is going above $10 soon....
Votes:
6
1
Quantexa News
01/22
Pacific Biosciences of California (NASDAQ:PACB) Trading 8.5% Higher – Here’s What Happened
Pacific Biosciences of California, Inc. (NASDAQ:PACB – Get Free Report)’s share price traded up 8.5% during mid-day trading on Wednesday . The company traded as high as $1.87 and last traded at $1.85....
Quantexa News
01/23
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Given Consensus Recommendation of “Moderate Buy” by Brokerages
NASDAQ:PACB – Get Free Report ) has been given a consensus rating of “Moderate Buy” by the twelve brokerages that are currently covering the company, Marketbeat reports. Six investment analysts have r...
Quantexa News
01/23
The Goldman Sachs Group Lowers Pacific Biosciences of California (NASDAQ:PACB) Price Target to $1.75
Pacific Biosciences of California (NASDAQ:PACB – Get Free Report) had its price objective lowered by research analysts at The Goldman Sachs Group from $2.25 to $1.75 in a report issued on Thursday,Ben...
Quantexa News
01/23
The Goldman Sachs Group Lowers Pacific Biosciences of California (NASDAQ:PACB) Price Target to $1.75
Pacific Biosciences of California ( NASDAQ:PACB – Get Free Report had its price target reduced by stock analysts at The Goldman Sachs Group from $2.25 to $1.75 in a note issued to investors on Thursda...
Quantexa News
01/23
Goldman Sachs Maintains Neutral on Pacific Biosciences, Lowers Price Target to $1.75 Goldman Sachs analyst Matthew Sykes maintains Pacific Biosciences (NASDAQ:PACB) with a Neutral and lowers the price target from $2.25 to $1.75.
Goldman Sachs Maintains Neutral on Pacific Biosciences, Lowers Price Target to $1.75 Goldman Sachs analyst Matthew Sykes maintains Pacific Biosciences with a Neutral and lowers the price target from $...
Quantexa News
01/23
Selling Your Pacific Biosciences of California Inc (NASDAQ: PACB) Stock? Here's What You Need To Know
Pacific Biosciences of California Inc (NASDAQ:PACB) shares, rose in value, with the stock price down by -10.56% to the previous day's close as strong demand from buyers drove the stock to $1.62. Acti...
Yahoo Finance Community
01/23
Comment
Roche apparently has a new short read sequencer that rivals Illumina’s. Are they going to pickup PACB long read tech and own the market? One thing for sure, PacB can’t seem to scale either technology on their own. Wouldn’t be surprised if Roche has been shorting this stock through various nefarious vehicles.....
Votes:
2
0
Quantexa News
01/24
The Goldman Sachs Group Issues Pessimistic Forecast for Pacific Biosciences of California (NASDAQ:PACB) Stock Price
Pacific Biosciences of California ( NASDAQ:PACB – Free Report had its target price decreased by The Goldman Sachs Group from $2.25 to $1.75 in a report released on Thursday morning, Benzinga reports....
Quantexa News
01/24
Pacific Biosciences of California (NASDAQ:PACB) Given New $1.75 Price Target at The Goldman Sachs Group
Pacific Biosciences of California ( NASDAQ:PACB – Free Report had its price target trimmed by The Goldman Sachs Group from $2.25 to $1.75 in a report issued on Thursday, Benzinga reports. The firm cur...
Quantexa News
01/24
Pacific Biosciences of California (NASDAQ:PACB) Stock Price Up 8.5% – Here’s What Happened
Pacific Biosciences of California, Inc. (NASDAQ:PACB – Get Free Report)’s stock price shot up 8.5% on Wednesday . The stock traded as high as $1.87 and last traded at $1.85. 2,130,217 shares were trad...
Quantexa News
01/24
Pacific Biosciences of California Inc (PACB) recent quarterly performance of -10.33% is not showing the real picture
As on Thursday, Pacific Biosciences of California Inc (NASDAQ: PACB) started slowly as it slid -8.84% to $1.65, before settling in for the price of $1.81 at the close. Taking a more long-term approach...
Quantexa News
01/25
Pacific Biosciences of California (NASDAQ:PACB) Price Target Cut to $1.75 by Analysts at The Goldman Sachs Group
Pacific Biosciences of California ( NASDAQ:PACB – Get Free Report had its price target reduced by research analysts at The Goldman Sachs Group from $2.25 to $1.75 in a note issued to investors on Thur...
Quantexa News
01/25
The Goldman Sachs Group Issues Pessimistic Forecast for Pacific Biosciences of California (NASDAQ:PACB) Stock Price
Pacific Biosciences of California ( NASDAQ:PACB – Get Free Report had its price objective decreased by analysts at The Goldman Sachs Group from $2.25 to $1.75 in a research report issued to clients an...
Quantexa News
01/26
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Receives $2.95 Consensus Target Price from Brokerages
Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Get Free Report ) has been given an average recommendation of “Moderate Buy” by the twelve ratings firms that are covering the stock, Marketbeat...
Quantexa News
01/26
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Receives $2.95 Consensus Price Target from Analysts
Shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB – Get Free Report) have been assigned an average recommendation of “Moderate Buy” from the twelve ratings firms that are currently coveri...
Quantexa News
01/26
JPMorgan Chase & Co. Buys 45,957 Shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB)
JPMorgan Chase & Co. increased its stake in shares of Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Free Report ) by 8.9% in the third quarter, according to the company in its most recent fi...
Quantexa News
01/26
The Goldman Sachs Group Issues Pessimistic Forecast for Pacific Biosciences of California (NASDAQ:PACB) Stock Price
Pacific Biosciences of California (NASDAQ:PACB – Free Report) had its target price decreased by The Goldman Sachs Group from $2.25 to $1.75 in a research note published on Thursday morning,Benzinga re...
Quantexa News
01/26
Assenagon Asset Management S.A. Has $390,000 Stock Position in Pacific Biosciences of California, Inc. (NASDAQ:PACB)
Assenagon Asset Management S.A. cut its stake in shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB – Free Report) by 24.4% in the 4th quarter, according to its most recent Form 13F filing...
Quantexa News
01/26
Assenagon Asset Management S.A. Sells 68,796 Shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB)
Assenagon Asset Management S.A. cut its position in Pacific Biosciences of California, Inc. (NASDAQ:PACB – Free Report) by 24.4% in the 4th quarter, according to the company in its most recent 13F fil...
Quantexa News
01/26
Impact Partnership Wealth LLC Boosts Stake in Pacific Biosciences of California, Inc. (NASDAQ:PACB)
Impact Partnership Wealth LLC lifted its holdings in Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Free Report ) by 29.5% in the 4th quarter, according to its most recent Form 13F filing wit...
Quantexa News
01/26
Impact Partnership Wealth LLC Acquires 11,566 Shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB)
Impact Partnership Wealth LLC raised its position in shares of Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Free Report ) by 29.5% in the fourth quarter, HoldingsChannel reports. The firm o...
Yahoo Finance News
01/27
Pacific Biosciences of California (PACB) Stock Moves -1.18%: What You Should Know
YAHOO FINANCE CHARTBOOK 44 charts that explain markets and the economy right now Pacific Biosciences of California (PACB) Stock Moves -1.18%: What You Should Know Zacks Equity Research Mon, Jan 27, 20...
Quantexa News
01/29
Stock Shock: The Unpredictable Rise and Fall of PACB—What's Driving the Drama?
UBS has recently reduced Pacific Biosciences of California Inc (PACB) stock to Neutral rating, as announced on November 11, 2024, according to Finviz . Earlier, on June 3, 2024, Jefferies had resumed...
Yahoo Finance Community
01/29
Comment
unfortunately there is a large short position that is hedging porky guiding lower (and then missing again). This will give some a chance to cover. the only posible miracle upside is some encroachment into short read market share, resulting in same revenue as last quarter....
Yahoo Finance Community
01/29
Comment
if elon is not too careful, there will be cut back to tesla purchases, and even space launches may need to be scrapped for wasteful spending. who needs electric vehicles right? mr musk may need to resort to becoming full time civil servant. Really, no one needs a moon or mars mission...all unecessary frivolous spending....
Votes:
2
0
Quantexa News
01/30
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Receives Consensus Rating of “Moderate Buy” from Analysts
Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Get Free Report ) has earned a consensus rating of “Moderate Buy” from the twelve ratings firms that are covering the stock, MarketBeat.com repo...
Quantexa News
01/30
PacBio Announces Appointment of Chris Smith to Board of Directors
MENLO PARK, Calif. , Jan. 30, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of Chris Smith...
Quantexa News
01/30
PacBio Announces Appointment of Chris Smith to Board of Directors
MENLO PARK, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of Chris Smith to its B...
Quantexa News
01/30
PacBio Announces Appointment of Chris Smith to Board of Directors
PacBio to leverage Chris' extensive expertise in diagnostics and laboratory testing markets, as Board Member David Meline steps down. MENLO PARK, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- PacBio (NAS...
Quantexa News
01/30
PacBio Welcomes Chris Smith to Its Board, Enhancing Leadership
Exciting Addition to PacBio's Board of Directors PacBio (NASDAQ: PACB), a prominent developer known for high-quality sequencing technology, has appointed Chris Smith to its Board of Directors. This s...
Quantexa News
01/30
PacBio Announces Appointment of Chris Smith to Board of Directors
MENLO PARK, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of Chris Smith t...
Quantexa News
01/30
PacBio Announces Appointment of Chris Smith to Board of Directors
MENLO PARK, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of Chris Smith t...
Quantexa News
01/30
Pacific Biosciences of California Appoints NeoGenomics CEO to Board of Directors
David W. Meline is Chief Financial Officer of Moderna, Inc. and Chief Financial Officer at Onyx Pharmaceuticals, Inc. Mr. Meline is also on the board of ABB Ltd., BioVex Group, Inc. and Los Angeles Ph...
Quantexa News
01/30
PacBio Announces Appointment of Chris Smith to Board of Directors
PacBio announced the appointment of Chris Smith to its Board of Directors, effective today. Mr. Smith is currently the Chief Executive Officer of NeoGenomics, Inc., a leading oncology testing services...
Yahoo Finance Community
01/30
Comment
pink bio. do something to get non-medical sequencing out to the public for a fair price. there's no need to wait for Fda or clinical approval. don't rely on sick people or investigators toying with rare diseases. push your product, don't just sit there waiting for rare disease research, or medical research that's going nowhere....
Votes:
1
0
Quantexa News
01/30
PacBio to Report Fourth Quarter 2024 Financial Results on February 13, 2025
MENLO PARK, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter 2024 financial results on Thur...
Quantexa News
01/30
PacBio to Report Fourth Quarter 2024 Financial Results on February 13, 2025
MENLO PARK, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter 2024 financial results on Thur...
Quantexa News
01/30
PacBio to Report Fourth Quarter 2024 Financial Results on February 13, 2025
MENLO PARK, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter 2024 financial results on Thur...
Quantexa News
01/30
PacBio to Report Fourth Quarter 2024 Financial Results on February 13, 2025
MENLO PARK, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter 2024 financial results on Thur...
Quantexa News
01/30
PacBio to Report Fourth Quarter 2024 Financial Results on February 13, 2025
MENLO PARK, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- PacBio PACB announced today that it will hold its quarterly conference call to discuss its fourth quarter 2024 financial results on Thursday, Febr...
Quantexa News
01/31
Pacific Biosciences of California Inc (PACB) volume hits 8.09 million: A New Opening for Investors
Pacific Biosciences of California Inc (NASDAQ: PACB) started the day on Thursday, with a price increase of 2.56% at $1.60, before settling in for the price of $1.56 at the close. Taking a more long-te...
Quantexa News
02/03
Pacific Biosciences of California Inc (PACB) Stock Faces 6.36% Weekly Volatility
The stock of Pacific Biosciences of California Inc (PACB) has gone down by -8.88% for the week, with a -13.97% drop in the past month and a -25.24% drop in the past quarter. The volatility ratio for t...
Yahoo Finance News
02/03
PacBio Announces Appointment of David Ruggiero as Head of Global Sales & Service
PacBio Announces Appointment of David Ruggiero as Head of Global Sales & Service PacBio Mon, Feb 3, 2025, 8:05 AM 3 min read In This Article: PACB -2.73% PacBio MENLO PARK, Calif., Feb. 03, 2025 (GLOB...
Quantexa News
02/03
PacBio Announces Appointment of David Ruggiero as Head of Global Sales & Service
MENLO PARK, Calif. , Feb. 03, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of David Ruggie...
Quantexa News
02/03
PacBio Announces Appointment of David Ruggiero as Head of Global Sales & Se
MENLO PARK, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of David Ruggier...
Quantexa News
02/03
PacBio Announces Appointment of David Ruggiero as Head of Global Sales & Service
MENLO PARK, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of David Ruggier...
Quantexa News
02/03
PacBio Announces Appointment of David Ruggiero as Head of Global Sales & Service
PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of David Ruggiero as the company's new Global Head of Sales & Service...
Quantexa News
02/03
PacBio appoints David Ruggiero as head of global sales, service
PacBio ( PACB ) announced the appointment of David Ruggiero as the company's new Global Head of Sales & Service. Ruggiero served as Senior Vice President, North America for Sinch. In his new role, Rug...
Quantexa News
02/03
PacBio Announces Appointment of David Ruggiero as Head of Global Sales & Service
MENLO PARK, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of David Ruggier...
Yahoo Finance Community
02/03
Comment
company really needs ceo to grow a spine. with their production under 100% on shore control, I don't want to be hearing excuses about reversal of Nafda or tarriffs cutting into their margins. I guess its fair they can't find a head of sales who has experience in the industry, but i guess sales accounting is sales. people out in the field do all the work....
Votes:
1
0
Quantexa News
02/03
PacBio Announces Appointment of David Ruggiero as Head of Global Sales & Service, Effective February 10, 2025
PacBio announced the appointment of David Ruggiero as the company?s new Global Head of Sales & Service. Mr. Ruggiero brings over two decades of experience in sales leadership within the technology and...
Quantexa News
02/03
PacBio Announces Appointment of David Ruggiero as Head of Global Sales & Service
MENLO PARK, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- PacBio PACB, a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of David Ruggiero as the c...
Quantexa News
02/03
PacBio Announces Appointment of David Ruggiero as Head of Global Sales & Service
MENLO PARK, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of David Ruggier...
Quantexa News
02/03
PacBio appoints David Ruggiero as head of global sales, service PacBio (PACB) announced the appointment of David Ruggiero as the company’s new Global Head of Sales & Service....
PacBio (PACB) announced the appointment of David Ruggiero as the company’s new Global Head of Sales & Service. Ruggiero served as Senior Vice President, North America for Sinch. In his new role, Ruggi...
Quantexa News
02/03
Sequencing Reagents Market Trends Analysis Report 2025-2030, with Illumina, QIAGEN, BGI, PacBio, Oxford Nanopore Technologies, Agilent Technologies, Standard BioTools, Takara Bio & Meridian Bioscience
Share Dublin, Feb. 03, 2025 (GLOBE NEWSWIRE) -- The "Sequencing Reagents Market Size, Share & Trends Analysis Report By Technology, By Type, By Application, By End Use, By Region, And Segment Forecas...
Quantexa News
02/04
Pacific Bio (PACB) names David Ruggiero as new Global Head of Sales
PacBio (NASDAQ: PACB ), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of David Ruggiero as the company's new Global Head of Sales & Service...
Quantexa News
02/04
Can Pacific Biosciences of California Inc (NASDAQ:PACB) Stock Be A Good Mid-Term Investment?
Pacific Biosciences of California Inc (NASDAQ:PACB) price closed lower on Monday, February 03, and dropping -5.19% below its previous close. A look at the daily price movement shows that the last clo...
Quantexa News
02/05
PacBio announces appointment of David Ruggiero as Head of Global Sales & Service
PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of David Ruggiero as the company’s new Global Head of Sales & Service....
Quantexa News
02/06
Pacific Biosciences of California (PACB) Projected to Post Earnings on Thursday
Pacific Biosciences of California (NASDAQ:PACB – Get Free Report) is projected to issue its quarterly earnings data after the market closes on Thursday, February 13th. Analysts expect the company to a...
Yahoo Finance Community
02/06
Comment
i am hopeful that this is temporary, and Congress, for the sake of our nation, will grow a spine and truly represent the people. Spending is what government is about, more careful spending, with only needed military (not gaza). Prudent spending is what will enable the health of our citizens economically and health/welfare (not robotics). A healthy economy for all is what will save pac bio...
Yahoo Finance Community
02/06
Comment
everyone who hope to keep out of global, prolonged recession, and clinging to pink bio losses. I entreat you to pay attention to the executive actions, and write your Congressmen. Use AI to do it. Get your kids active and have them prompt the letters. Buy them the envelope and stamp and have them drop it in the mail.I will take that action for the sake of our nation....
Votes:
1
3
Yahoo Finance Community
02/06
Comment
Dear Congressman/Person. you represent us regardless of your party. There is a threat our nation has never faced before in this new era of accelerated labor loss. pac bio's health depends on the resolution of this. our kids economic health depends on the proper resolution of this. the new administration needs to be neutered and put back in its place....
Votes:
2
4
Yahoo Finance Community
02/06
Comment
ok, hopefully gridlock of the same kind during obama years. the people don't need this. Litigation needs to proceed on behalf of the nation.This is bigger than Democrats versus Republicans. It goes to the core of our constitutional republic,” said the EPW Ranking Member...
Votes:
1
0
Yahoo Finance Community
02/06
Comment
ok, cool, its all on pink bio to perform. hopefully congress has the spine to take care of the madmanIt's a complex process, but Congress does have mechanisms to check the president's tariff authority. (and everything else need to check an irrational person)...
Quantexa News
02/07
Sequencing Reagents Industry Eyes $15.84 Billion Valuation by 2030 - Thermo Fisher Scientific, Abzena, Illumina, QIAGEN, and Pacific Biosciences of California Lead the Competition
Share Dublin, Feb. 07, 2025 (GLOBE NEWSWIRE) -- The "Sequencing Reagents Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to ResearchAndMarke...
Quantexa News
02/07
Sequencing Reagents Industry Eyes $15.84 Billion Valuation by 2030 - Thermo Fisher Scientific, Abzena, Illumina, QIAGEN, and Pacific Biosciences of California Lead the Competition
Research and Markets 3 min read Sequencing Reagents Market Dublin, Feb. 07, 2025 (GLOBE NEWSWIRE) -- The "Sequencing Reagents Market - Global Industry Size, Share, Trends, Opportunity, and Forecast...
Quantexa News
02/07
Sequencing Reagents Industry Eyes $15.84 Billion Valuation by 2030 - Thermo Fisher Scientific, Abzena, Illumina, QIAGEN, and Pacific Biosciences of California Lead the Competition
GlobeNewswire Dublin, Feb. 07, 2025 (GLOBE NEWSWIRE) -- The "Sequencing Reagents Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to Research...
Quantexa News
02/07
Sequencing Reagents Industry Eyes $15.84 Billion Valuation by 2030 - Thermo Fisher Scientific, Abzena, Illumina, QIAGEN, and Pacific Biosciences of California Lead the Competition
Dublin, Feb. 07, 2025 (GLOBE NEWSWIRE) -- The "Sequencing Reagents Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2020-2030F" report has been added to ResearchAndMarkets.com'...
Quantexa News
02/07
Pacific Biosciences of California Inc (NASDAQ: PACB) Now Carries A 12-Month Price Target Of $4.
Pacific Biosciences of California Inc (NASDAQ:PACB)'s traded shares stood at 12.97 million during the last session, with the company's beta value hitting 1.85. At the close of trading, the stock's pri...
Yahoo Finance Community
02/09
Comment
The ER this week is probaby predictabe: a 5-10% miss on revenure, may be a penny or two beat on EPS because of the layoffs kicking in and turning some lights off to reduce overhead. Unles they have some big news the stock is range bound $1.50-$1.90...
Votes:
2
1
Yahoo Finance Community
02/10
Comment
Is this movement due to the Trump Administration changes in NIH funding of research indirect costs? Is the testing equipment like PACB's considered to be direct or indirect costs under the NIH grants? Or is only the general overhead, like the buildings and utilities and administrative staff, the types of costs that are subject to the cap on indirect costs?...
Votes:
2
1
Yahoo Finance Community
02/10
Comment
maybe the doge kid will spare research that potentially saves costs and has a eugenics potential? after all they learned on grants to study dead sea scrolls or something like that. we can't let china lead in gene sequencing and perfect the perfect humanoids...
Votes:
2
1
Yahoo Finance Community
02/10
Comment
There is no meaningful support below this current level so it is likely to turn around from here and go northCURRENT PRICE1.4, at support, 1.33 ± 0.131 type double, strength 2SUPPORT BELOWNone.RESISTANCE ABOVE+16.9% at 1.64 ± 0.162 type triple+, strength 10+45.4% at 2.04 ± 0.201 type triple+, strength 10+82.1% at 2.55 ± 0.252 type single, strength 8...
Votes:
2
3
Quantexa News
02/10
Why Pacific Biosciences of California, Inc.'s (PACB) Stock Is Down 14.74%
Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Pacific Biosciences of California, Inc. before investing. In this article, we go...
Quantexa News
02/11
Analysts Offer Insights on Healthcare Companies: Pacific Biosciences (PACB), Immunovant (IMVT) and 4D Molecular Therapeutics (FDMT)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Pacific Biosciences ( PACB – Research Report ), Immunovant ( IMVT – Research Report ) and 4D Molecular...
Quantexa News
02/11
Barclays Keeps Their Hold Rating on Pacific Biosciences (PACB)
In a report released today, Luke Sergott from Barclays maintained a Hold rating on Pacific Biosciences ( PACB – Research Report ), with a price target of . The company's shares closed yesterday at $1....
Quantexa News
02/12
Moloney Securities Asset Management LLC Lowers Holdings in Pacific Biosciences of California, Inc. (NASDAQ:PACB)
Moloney Securities Asset Management LLC reduced its stake in shares of Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Free Report ) by 39.0% in the fourth quarter, according to the company in...
Quantexa News
02/12
Moloney Securities Asset Management LLC Cuts Stake in Pacific Biosciences of California, Inc. (NASDAQ:PACB)
Moloney Securities Asset Management LLC cut its position in Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Free Report ) by 39.0% in the 4th quarter, according to its most recent disclosure w...
Quantexa News
02/12
Pacific Biosciences of California (PACB) to Release Quarterly Earnings on Thursday
Pacific Biosciences of California ( NASDAQ:PACB – Get Free Report ) will likely be issuing its quarterly earnings data after the market closes on Thursday, February 13th. Analysts expect the company t...
Quantexa News
02/12
Pacific Biosciences of California Inc (PACB) Q4 2024 Earnings Report Preview: What To Expect
Pacific Biosciences of California Inc ( NASDAQ:PACB ) is set to release its Q4 2024 earnings on Feb 13, 2025. The consensus estimate for Q4 2024 revenue is $40.16 million, and the earnings are expecte...
Yahoo Finance Community
02/12
Comment
SoftBank exchanged $209m debt for 20.5m shares. That's $10.20 per share.Strengthened financial position: Enhanced our balance sheet by exchanging $459m notes due 2028 for $200m in newly issued notes due August 2029, along with approx. 20.5m shares of stock and $50m in cash. $200m of the debt due 2028 replaced by $200m debt due 2029 $50m of the debt paid back in cash remaining $209m debt paid back with 20.5m shares = $10.20 per share This is awesome. Bright future. SoftBank is betting the stock will be worth more than $10/share soon. They have deep insights into this company....
Votes:
1
1
Quantexa News
02/12
PacBio (PACB) Q4 Earnings Report Preview: What To Look For
Stock Story - Genomics company Pacific Biosciences of California (NASDAQ: PACB ) will be announcing earnings results tomorrow after market hours. Here's what investors should know. PacBio missed an...
Yahoo Finance Community
02/12
Comment
SoftBank's Vision Fund investments, including its investment in Pacific Biosciences (PacBio), have contributed to significant financial losses. For the fiscal third quarter, SoftBank reported a $2.4 billion loss. This loss was primarily driven by declines in the value of its portfolio companies, including PacBio...
Quantexa News
02/13
Sumitomo Mitsui Trust Group Inc. Trims Stock Holdings in Pacific Biosciences of California, Inc. (NASDAQ:PACB)
Sumitomo Mitsui Trust Group Inc. decreased its position in Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Free Report ) by 14.2% in the fourth quarter, HoldingsChannel.com reports. The fund o...
Reddit
02/13
$PACB, Did ARK investment know something that we don’t about this stock!!!
$PACB: ARK investment has increased its position in PACB stock in January and February. ARK Investment has bought multiple shares of PACB stock in recent months, including 344,000 shares in February 2...
Reddit
02/13
$PACB, Did ARK investment know something that we don’t about this stock!!!
$PACB: ARK investment has increased its position in PACB stock in January and February. ARK Investment has bought multiple shares of PACB stock in recent months, including 344,000 shares in February 2...
Yahoo Finance Community
02/13
Comment
Has anyone dug into the convertible note exchanges with SoftBank over the past 18 months? The original $900 million in notes had a conversion price of $43.50 per share, which shows you how far PACB has fallen from the highs of February 2021. The first exchange was a bit questionable, since PACB lowered the conversion price to $21.50 and only got a slight reduction in the interest rate and a couple more years on the term. The more recent exchange changed the conversion price to $4.89 (from the original $43.50), but SoftBank also converted $209 million in debt into equity at $10.22 per share. PACB could have just refinanced the debt in 2028 without any dilution. That could mean that the company does not expect cash flow to be high enough by 2028 to support the refinancing. I don't know what to make of the exchange transactions....
Votes:
3
3
Quantexa News
02/13
PacBio Announces Fourth Quarter and Fiscal Year 2024 Financial Results
MENLO PARK, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2024. Fourth quarter results This ar...
Quantexa News
02/13
PacBio Announces Fourth Quarter and Fiscal Year 2024 Financial Results
MENLO PARK, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2024. Fourth quarter results Gross m...
Quantexa News
02/13
PacBio Announces Fourth Quarter and Fiscal Year 2024 Financial Results
February 13, 2025 at 04:06 pm EST MENLO PARK, Calif. Feb. 13, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2024...
Quantexa News
02/13
PacBio Announces Fourth Quarter and Fiscal Year 2024 Financial Results
MENLO PARK, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2024. Fourth quarter results Revenue...
Quantexa News
02/13
PacBio Announces Fourth Quarter and Fiscal Year 2024 Financial Results
MENLO PARK, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2024. Fourth quarter results Revenue...
Quantexa News
02/13
PacBio Announces Fourth Quarter and Fiscal Year 2024 Financial Results
MENLO PARK, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2024. Fourth quarter results Revenue...
Quantexa News
02/13
PacBio Announces Fourth Quarter and Fiscal Year 2024 Financial Results
MENLO PARK, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2024. Fourth quarter results Revenue...
Quantexa News
02/13
PacBio Announces Fourth Quarter and Fiscal Year 2024 Financial Results
MENLO PARK, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2024. Fourth quarter results Revenue...
Quantexa News
02/13
PacBio Reveals Fiscal Year 2024 Financial Overview and Performance
Financial Results Overview PacBio (NASDAQ: PACB) recently announced its financial performance for the fourth quarter and the entire fiscal year ending on December 31, 2024. The company reported a rev...
Quantexa News
02/13
Pacific Biosciences of California (NASDAQ:PACB) Releases Earnings Results, Hits Expectations
Pacific Biosciences of California ( NASDAQ:PACB – Get Free Report ) announced its quarterly earnings data on Thursday. The biotechnology company reported ($0.20) earnings per share for the quarter, hi...
Quantexa News
02/13
PacBio reports Q4 EPS (20c), consensus (17c) Reports Q4 revenue $39.22M, consensus $40.68M. “2024 was a challenging yet transformative year for PacBio (PACB), marked by...
Reports Q4 revenue $39.22M, consensus $40.68M. “2024 was a challenging yet transformative year for PacBio (PACB), marked by the successful launch of new products, disciplined cost management, and stra...
Yahoo Finance Community
02/13
Comment
So, definitely sounds like the NIH cap on indirect costs pertains to PACB equipment used for research. I had read that PACB equipment was not necessarily indirect costs, but that seems to be incorrect. However, there has to be the ability to charge the grant for the use of the PACB equipment as direct expense. How do we have a genomics revolution without the equipment and consumables from PACB and Illumina? If all developed countries need to reduce healthcare costs, how is this not a focus of every government?...
Votes:
1
0
Quantexa News
02/13
PacBio's Q4 and Year-End 2024 Results: Challenges and Innovations
Introduction to PacBio's Q4 Performance Pacific Biosciences of California, Inc. (NASDAQ: PACB) recently shared their financial results for the fourth quarter and the full fiscal year ending December...
Yahoo Finance News
02/13
Pacific Biosciences of California (PACB) Reports Q4 Loss, Tops Revenue Estimates
Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Pacific Biosciences of California (PACB) Reports Q4 Loss, Tops Revenue Estimates Zacks Equity Research Thu, Feb 13,...
Quantexa News
02/13
Pacific Biosciences of California (NASDAQ:PACB) Releases Quarterly Earnings Results, Meets Expectations
Pacific Biosciences of California ( NASDAQ:PACB – Get Free Report ) announced its earnings results on Thursday. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, mee...
Quantexa News
02/13
Pacific Biosciences of California (NASDAQ:PACB) Releases Earnings Results, Meets Estimates
Pacific Biosciences of California ( NASDAQ:PACB – Get Free Report ) posted its quarterly earnings data on Thursday. The biotechnology company reported ($0.20) earnings per share for the quarter, meeti...
Quantexa News
02/13
Pacbio Announces Fourth Quarter And Fiscal Year 2024 Financial Results
MENAFN - GlobeNewsWire - Nasdaq) MENLO PARK, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2024....
Yahoo Finance News
02/13
Compared to Estimates, Pacific Biosciences (PACB) Q4 Earnings: A Look at Key Metrics
Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Compared to Estimates, Pacific Biosciences (PACB) Q4 Earnings: A Look at Key Metrics Zacks Equity Research Thu, Feb...
Quantexa News
02/13
PacBio Announces Fourth Quarter and Fiscal Year 2024 Financial Results
PacBio Announces Fourth Quarter and Fiscal Year 2024 Financial Results PacBio Thu, February 13, 2025 at 10:05 PM GMT+1 22 min read In This Article PACB PacBio MENLO PARK, Calif., Feb. 13,...
Quantexa News
02/13
Compared to Estimates, Pacific Biosciences (PACB) Q4 Earnings: A Look at Key Metrics
Zacks Equity Research 2 min read In This Article For the quarter ended December 2024, Pacific Biosciences of California (PACB) reported revenue of $39.22 million, down 32.8% over the same period la...
Quantexa News
02/13
PacBio Announces Fourth Quarter and Fiscal Year 2024 Financial Results
MENLO PARK, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2024. Fourth quarter results Revenue...
Quantexa News
02/13
Pacific Biosciences of California, Inc. (PACB) Q4 2024 Earnings Call Transcript
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q4 2024 Earnings Conference Call February 13, 2025 4:30 PM ET Company Participants Todd Friedman - Senior Director, Finance and Investor Relatio...
Quantexa News
02/13
https://seekingalpha.com/article/4758271-pacific-biosciences-of-california-inc-pacb-q4-2024-earnings-call-transcript
SA Transcripts Pacific Biosciences of California, Inc. ( NASDAQ: PACB ) Q4 2024 Earnings Conference Call February 13, 2025 4:30 PM ET Company Participants Todd Friedman - Senior Director, Finance...
Quantexa News
02/13
Pacific Biosciences of California : PacBio Q4 2024 Earnings Presentation
February 13, 2025 at 10:50 pm EST PacBio Q4 2024 Earnings Presentation February 13, 2025 Fourth Quarter 2024 Earnings Call Business & Commercial Updates Christian Henry, President & CEO Q4 r...
Yahoo Finance News
02/14
Pacific Biosciences of California Inc (PACB) Q4 2024 Earnings Call Highlights: Navigating ...
Pacific Biosciences of California Inc (PACB) Q4 2024 Earnings Call Highlights: Navigating ... GuruFocus News Fri, Feb 14, 2025, 2:21 AM 4 min read In This Article: PACB +25.00% Q4 2024 Revenue: $39.2...
Quantexa News
02/14
Pacific Biosciences Of California, Inc. Q4 Earnings Summary
(RTTNews) - Below are the earnings highlights for Pacific Biosciences of California, Inc. (PACB): Earnings: $3.57 million in Q4 vs. -$82.02 million in the same period last year. EPS: -$0.49 in Q4 vs...
Quantexa News
02/14
PacBio Announces Fourth Quarter and Fiscal Year 2024 Financial Results
MENLO PARK, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter and fiscal year ended December 31, 2024. Fourth quarter results Revenue...
Quantexa News
02/14
UBS Adjusts Price Target on Pacific Biosciences of California to $1.50 From $2, Keeps Neutral Rating
Pacific Biosciences of California, Inc. is a life science technology company. It is engaged in designing, developing, and manufacturing advanced sequencing solutions that enable scientists and clinica...
Yahoo Finance Community
02/14
Comment
Sales growth in Asia Pacific, especially China, is a big opportunity for Ruggiero. To offset challenging macroeconomic circumstances in the US. Both research and clinical fields in China. Competitors are banned but this company won't be because there is no viable alternative (Chinese or other) for long-read sequencing equipment....
Votes:
1
1
Quantexa News
02/14
PacBio price target lowered to $3.50 from $4 at TD Cowen TD Cowen lowered the firm’s price target on PacBio (PACB) to $3.50 from $4 and keeps a Buy...
TD Cowen lowered the firm’s price target on PacBio (PACB) to $3.50 from $4 and keeps a Buy rating on the shares. The firm said its sales guidance was below consensus bt long-term, they see an attracti...
Quantexa News
02/14
PacBio price target lowered to $3.50 from $4 at TD Cowen
TD Cowen lowered the firm's price target on PacBio ( PACB ) to $3.50 from $4 and keeps a Buy rating on the shares. The firm said its sales guidance was below consensus bt long-term, they see an attrac...
Yahoo Finance News
02/14
PACB Stock Down Following In-Line Q4 Earnings, Revio Shipments Fall
PACB Stock Down Following In-Line Q4 Earnings, Revio Shipments Fall Zacks Equity Research Fri, Feb 14, 2025, 11:04 AM 6 min read In This Article: PACB +25.00% BSX -0.03% CAH -0.45% RMD -2.71% Pacific...
Quantexa News
02/14
PacBio should return to growth over time, says Canaccord
Canaccord reiterates a Buy rating on PacBio ( PACB ) with a $3 price target following the company's Q4 report. The firm says that although PacBio forecasts modest sales growth in 2025, it remains opti...
Quantexa News
02/14
PacBio should return to growth over time, says Canaccord Canaccord reiterates a Buy rating on PacBio (PACB) with a $3 price target following the company’s Q4 report....
Canaccord reiterates a Buy rating on PacBio (PACB) with a $3 price target following the company’s Q4 report. The firm says that although PacBio forecasts modest sales growth in 2025, it remains optimi...
Quantexa News
02/14
Goodyear Tire & Rubber Posts Upbeat Results, Joins Nu Skin, Pacific Biosciences of California, Airbnb, Roku And Other Big Stocks Moving Higher On Friday
U.S. stocks were mostly lower, with the Dow Jones falling around 100 points on Friday. Shares of The Goodyear Tire & Rubber Company (NASDAQ:GT) rose sharply during Friday's session after the company...
Quantexa News
02/14
SoftBank reports new stakes in PacBio, Recursion Pharmaceuticals
SoftBank disclosed a 20.45M share position in PacBio ( PACB ) and 14.67M share position in Recursion Pharmaceuticals ( RXRX ) in a regulatory filing detailing its holdings as of December 31, 2024. Sof...
Quantexa News
02/14
Goodyear Tire & Rubber Posts Upbeat Results, Joins Nu Skin, Pacific Biosciences of California, Airbnb, Roku And Other Big Stocks Moving Higher On Friday
U.S. stocks were mostly lower, with the Dow Jones falling around 100 points on Friday. Shares of The Goodyear Tire & Rubber Company GT rose sharply during Friday's session after the company reported...
Quantexa News
02/14
Goodyear Tire & Rubber Posts Upbeat Results, Joins Nu Skin, Pacific Biosciences of California, Airbnb, Roku And Other Big Stocks Moving Higher On Friday
U.S. stocks were mostly lower, with the Dow Jones falling around 100 points on Friday. Shares of The Goodyear Tire & Rubber Company (NASDAQ:GT) rose sharply during Friday's session after the company...
Reddit
02/14
$PACB , Is something big going to happen with PACB stock with the news just few minutes ago???
$PACB : SoftBank disclosed a 20.45M share position in PacBio (PACB) stock. This stake represents about 7.5% of SoftBank's holdings in PACB. The investment reflects SoftBank's confidence in PACB's po...
Reddit
02/14
$PACB , Is something big going to happen with PACB stock with the news just few minutes ago???
$PACB : SoftBank disclosed a 20.45M share position in PacBio (PACB) stock. This stake represents about 7.5% of SoftBank's holdings in PACB. The investment reflects SoftBank's confidence in PACB's po...
Reddit
02/14
$PACB , Is something big going to happen with PACB stock with the news just few minutes ago???
$PACB : SoftBank disclosed a 20.45M share position in PacBio (PACB) stock. This stake represents about 7.5% of SoftBank's holdings in PACB. The investment reflects SoftBank's confidence in PACB's po...
Quantexa News
02/14
Stephens Reiterates Overweight Rating for Pacific Biosciences of California (NASDAQ:PACB)
Pacific Biosciences of California ( – ‘s stock had its “overweight” rating restated by research analysts at Stephens in a research report issued on Friday, reports. They currently have a $2.50 price t...
Yahoo Finance Community
02/14
Comment
Look at the bigger picture. TAM expansion due to clinical adoption. That will be a whole another level compared to sequencing for research purposes only. Clinical market penetration is around the corner. It would be irresponsible to bake that expectation into the guidance for 2025, but it may happen sooner than we think. When it does happen this is a $10+ per share stock overnight. And $100+ is not unimaginable....
Votes:
3
1
Quantexa News
02/14
SoftBank reports new stakes in PacBio, Recursion Pharmaceuticals SoftBank disclosed a 20.45M share position in PacBio (PACB) and 14.67M share position in Recursion Pharmaceuticals (RXRX) in...
SoftBank disclosed a 20.45M share position in PacBio (PACB) and 14.67M share position in Recursion Pharmaceuticals (RXRX) in a regulatory filing detailing its holdings as of December 31, 2024. SoftBan...
Yahoo Finance Community
02/14
Comment
You know...not long ago I was sitting on Bloom Energy stocks that hung around $13.00 ish what seemed forever... And on one Friday morning suddenly with big News it jumped from $13.00 to $21.00 in just hours... Oh shorts made their comments that were all wrong... a couple of days later.. Shorts were caught once again in a Squeeze... you know that got rid of a lot of Shorts... Overall it was figured out that the Shorts lost a combined total of 1 billion $$ over two weeks... Put your money down to Short this more in the future... I dare ya...
Votes:
3
0
Yahoo Finance Community
02/14
Comment
Please let me know your thoughts. a) What is so special about this company's products. Why can't customers just FEDEX DNA results to a lab to run this analysis. So, if this is the case, the need for multiple systems installed across a country diminishes. The PhotoMat of the 1980's went out of business.b) With all the overcapacity being generated with LLM computational capacity, will they start looking for other problems to work on (not LLMs, but the computational capacity in search of problems) and would this type of system be one to provide more data for subsequent drug discovery and analysis?My shares did nicely today, yes they did.I want to be bullish but I want to understand the market forces....
Votes:
2
2
Quantexa News
02/15
Pacific Biosciences of California (NASDAQ:PACB) Upgraded to “Sell” at StockNews.com
StockNews.com upgraded shares of Pacific Biosciences of California ( NASDAQ:PACB – Free Report to a sell rating in a report issued on Friday. Several other research analysts also recently weighed in...
Quantexa News
02/15
Stephens Reiterates Overweight Rating for Pacific Biosciences of California (NASDAQ:PACB)
Stephens reiterated their overweight rating on shares of Pacific Biosciences of California ( NASDAQ:PACB – Free Report in a report published on Friday, Benzinga reports. The brokerage currently has a...
Quantexa News
02/15
Pacific Biosciences of California's (PACB) Overweight Rating Reaffirmed at Stephens
Stephens reaffirmed their overweight rating on shares of Pacific Biosciences of California ( NASDAQ:PACB – Free Report in a report released on Friday, Benzinga reports. Stephens currently has a $2.50...
Yahoo Finance News
02/15
Pacific Biosciences of California Full Year 2024 Earnings: EPS Beats Expectations
Pacific Biosciences of California Full Year 2024 Earnings: EPS Beats Expectations editorial-team@simplywallst.com (Simply Wall St) Sat, Feb 15, 2025, 7:07 AM 1 min read In This Article: PACB +25.00% P...
Quantexa News
02/15
Pacific Biosciences of California (NASDAQ:PACB) Issues Quarterly Earnings Results
Pacific Biosciences of California (NASDAQ:PACB – Get Free Report) issued its quarterly earnings results on Thursday. The biotechnology company reported ($0.20) EPS for the quarter, meeting the consens...
Quantexa News
02/15
Pacific Biosciences of California EPS Beats Expectations
Revenue was in line with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 15%. In the last 12 months, the only revenue segment was Integrated Platform for Genetic Analysis c...
Quantexa News
02/15
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Q4 2024 Earnings Call Transcript
Pacific Biosciences of California, Inc. (NASDAQ: PACB ) Q4 2024 Earnings Call Transcript February 13, 2025 Pacific Biosciences of California, Inc. beats earnings expectations. Reported EPS is $0.51,...
Quantexa News
02/16
Pacific Biosciences of California (NASDAQ:PACB) Shares Gap Down – Here’s Why
Pacific Biosciences of California, Inc. (NASDAQ:PACB – Get Free Report)’s share price gapped down prior to trading on Friday . The stock had previously closed at $1.48, but opened at $1.43. Pacific Bi...
Yahoo Finance Community
02/16
Comment
They have $390M in cash and equivalent. Their operating expenses were $160M last quarter but normally they spend around $100M. That means the next Q or the one after they will need to raise money by either new stock offering and/or a new debt instrument....
Yahoo Finance Community
02/16
Comment
well, it helps a tiny bit. useless purchases, bad decision making over all due to a flabby leadership. these people had been fullfilment of umbrellas when it was raining, then it stopped raining and they are still heading for cover.Generally, impairment losses on fixed assets, such as machinery or buildings, can be deducted from taxable income, thereby reducing the overall tax liability....
Quantexa News
02/17
Pacific Biosciences of California (NASDAQ:PACB) Upgraded at StockNews.com
StockNews.com upgraded shares of Pacific Biosciences of California ( NASDAQ:PACB – Free Report to a sell rating in a research note issued to investors on Friday morning. Get Pacific Biosciences of Ca...
Quantexa News
02/17
Pacific Biosciences of California (NASDAQ:PACB) Rating Increased to Sell at StockNews.com
StockNews.com upgraded shares of Pacific Biosciences of California ( NASDAQ:PACB – Free Report to a sell rating in a research note issued to investors on Friday morning. PACB has been the topic of a...
Quantexa News
02/17
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Given Average Recommendation of “Moderate Buy” by Analysts
Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Get Free Report ) has received an average recommendation of “Moderate Buy” from the thirteen ratings firms that are presently covering the firm,...
Quantexa News
02/17
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Receives Consensus Rating of “Moderate Buy” from Brokerages
Pacific Biosciences of California, Inc. (NASDAQ:PACB – Get Free Report) has been assigned a consensus recommendation of “Moderate Buy” from the thirteen ratings firms that are currently covering the c...
Quantexa News
02/17
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Given Average Recommendation of "Moderate Buy" by Analysts
Pacific Biosciences of California, Inc. (NASDAQ:PACB - Get Free Report) has received an average recommendation of "Moderate Buy" from the thirteen ratings firms that are presently covering the firm, M...
Quantexa News
02/17
Pacific Biosciences of California's (PACB) “Overweight” Rating Reiterated at Stephens
Stephens restated their overweight rating on shares of Pacific Biosciences of California ( NASDAQ:PACB – Free Report in a report issued on Friday morning, Benzinga reports. The firm currently has a $2...
Yahoo Finance Community
02/17
Comment
do not feed the muskrat with 100% tarriffs on EV and don't buy the EV from the muskrat!Elon Musk could face expulsion from the historic Royal Society scientific institution after the group agreed to call a meeting to discuss Fellows’ behaviors following a revolt from scientists.The institution, which was founded in 1660, plans to hold a meeting on March 3 to debate “principles around public pronouncements and behaviours of Fellows...
Votes:
2
0
Quantexa News
02/17
PacBio grants equity incentive award to new employee PacBio (PACB) announced that the Compensation Committee of the Company’s Board of Directors granted a non-qualified stock option...
PacBio (PACB) announced that the Compensation Committee of the Company’s Board of Directors granted a non-qualified stock option covering 400,000 shares of PacBio common stock, and restricted stock un...
Quantexa News
02/18
Morgan Stanley Sticks to Its Hold Rating for Pacific Biosciences (PACB)
Morgan Stanley analyst Tejas Savant maintained a Hold rating on Pacific Biosciences ( PACB – Research Report ) today and set a price target of $2.00. The company's shares closed last Friday at $1.85....
Quantexa News
02/18
Unusually active option classes on open February 18th
Unusual total active option classes on open include: SPDR Euro STOXX (FEZ), Pac Bio ( PACB ), Altimeter Growth ( GRAB ), Oscar Health ( OSCR ), Medtronic ( MDT ), ARK Genomic Revolution Multi Sector E...
Quantexa News
02/18
Traders Purchase High Volume of Pacific Biosciences of California Call Options (NASDAQ:PACB)
Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Get Free Report ) was the target of unusually large options trading activity on Tuesday. Stock traders acquired 31,944 call options on the stock...
Quantexa News
02/19
The Goldman Sachs Group Has Lowered Expectations for Pacific Biosciences of California (NASDAQ:PACB) Stock Price
Pacific Biosciences of California ( NASDAQ:PACB – Free Report had its price objective decreased by The Goldman Sachs Group from $1.75 to $1.50 in a report published on Tuesday, Benzinga reports. The G...
Quantexa News
02/19
Pacific Biosciences of California (NASDAQ:PACB) Given New $1.50 Price Target at The Goldman Sachs Group
Pacific Biosciences of California ( NASDAQ:PACB – Free Report had its target price trimmed by The Goldman Sachs Group from $1.75 to $1.50 in a research report released on Tuesday, Benzinga reports. Th...
Quantexa News
02/19
Traders Purchase High Volume of Call Options on Pacific Biosciences of California (NASDAQ:PACB)
Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Get Free Report ) saw some unusual options trading activity on Tuesday. Stock investors bought 31,944 call options on the stock. This is an incr...
Quantexa News
02/19
Traders Purchase High Volume of Call Options on Pacific Biosciences of California (NASDAQ:PACB)
Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Get Free Report ) saw unusually large options trading activity on Tuesday. Stock investors bought 31,944 call options on the company. This is an...
Quantexa News
02/19
Shares Of Pacific Biosciences of California Inc (NASDAQ: PACB) Gain 16.87% In A Month
Pacific Biosciences of California Inc (NASDAQ:PACB) has a beta value of 1.85 and has seen 19.71 million shares traded in the last trading session. The company, currently valued at $512.12M, closed the...
Yahoo Finance News
02/19
PacBio to Participate in TD Cowen's 45th Annual Health Care Conference
Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now PacBio to Participate in TD Cowen's 45th Annual Health Care Conference PacBio Wed, Feb 19, 2025, 1:05 PM 1 min read...
Quantexa News
02/19
Traders Purchase High Volume of Pacific Biosciences of California Call Options (NASDAQ:PACB)
Pacific Biosciences of California, Inc. (NASDAQ:PACB - Get Free Report) was the target of unusually large options trading activity on Tuesday. Stock traders acquired 31,944 call options on the stock....
Quantexa News
02/20
The Goldman Sachs Group Lowers Pacific Biosciences of California (NASDAQ:PACB) Price Target to $1.50
Pacific Biosciences of California (NASDAQ:PACB – Get Free Report) had its price target dropped by research analysts at The Goldman Sachs Group from $1.75 to $1.50 in a research report issued on Tuesda...
Quantexa News
02/20
PacBio price target lowered to $2 from $2.50 at Piper Sandler
Piper Sandler lowered the firm's price target on PacBio ( PACB ) to $2 from $2.50 following quarterly results. The firm keeps a Neutral rating on the shares. Discover the Best Stocks and Maximize You...
Quantexa News
02/20
Pacific Biosciences (PACB) Gets a Hold from Piper Sandler
In a report released today, David Westenberg from Piper Sandler reiterated a Hold rating on Pacific Biosciences ( PACB – Research Report ), with a price target of . The company's shares closed yesterd...
Quantexa News
02/20
Pacific Biosciences of California (NASDAQ:PACB) Given Neutral Rating at Piper Sandler
Pacific Biosciences of California ( NASDAQ:PACB – Get Free Report ‘s stock had its “neutral” rating reiterated by research analysts at Piper Sandler in a research report issued to clients and investor...
Quantexa News
02/20
Pacific Biosciences of California (NASDAQ:PACB) Given Neutral Rating at Piper Sandler
Pacific Biosciences of California ( NASDAQ:PACB – Get Free Report ‘s stock had its “neutral” rating reissued by Piper Sandler in a research report issued on Thursday, Benzinga reports. They presently...
Quantexa News
02/21
Michele Farmer Sells 24,349 Shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB) Stock
Pacific Biosciences of California, Inc. ( – ) insider Michele Farmer sold 24,349 shares of Pacific Biosciences of California stock in a transaction on Tuesday, February 18th. The stock was sold at an...
Quantexa News
02/21
Pacific Biosciences of California Inc (PACB) surge 20.59% in a week: will this be a lucky break through?
As on Thursday, Pacific Biosciences of California Inc (NASDAQ: PACB) started slowly as it slid -7.34% to $1.64, before settling in for the price of $1.77 at the close. Taking a more long-term approach...
Quantexa News
02/22
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Insider Michele Farmer Sells 24,349 Shares
Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Get Free Report ) insider Michele Farmer sold 24,349 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. Th...
Yahoo Finance News
02/22
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Analysts Just Slashed This Year's Revenue Estimates By 14%
Unlock stock picks and a broker-level newsfeed that powers Wall Street. Upgrade Now Pacific Biosciences of California, Inc. (NASDAQ:PACB) Analysts Just Slashed This Year's Revenue Estimates By 14% edi...
Quantexa News
02/22
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Analysts Just Slashed This Year's Revenue Estimates By 14%
editorial-team@simplywallst.com (Simply Wall St) 3 MINUTES_READ IN_THIS_ARTICLE Market forces rained on the parade of Pacific Biosciences of California, Inc. NASDAQ:PACB ) shareholders today, when...
Quantexa News
02/22
Pacific Biosciences of California, Inc. (NASDAQ:PACB) Analysts Just Slashed This Year's Revenue Estimates By 14%
Market forces rained on the parade of Pacific Biosciences of California, Inc. NASDAQ:PACB ) shareholders today, when the analysts downgraded their forecasts for this year. Revenue estimates were cut s...
Quantexa News
02/23
Pacific Biosciences of California's (PACB) Neutral Rating Reiterated at Piper Sandler
Piper Sandler restated their neutral rating on shares of Pacific Biosciences of California ( NASDAQ:PACB – Free Report in a research note published on Thursday, Benzinga reports. They currently have a...
Quantexa News
02/24
Analyzing the Price-to-Earnings Ratio of Pacific Biosciences of California Inc (PACB)
The 36-month beta value for PACB is also noteworthy at 1.85. There are mixed opinions on the stock, with 6 analysts rating it as a “buy,” 1 rating it as “overweight,” 8 rating it as “hold,” and 0 rati...
Quantexa News
02/25
Pacific Biosciences of California (NASDAQ:PACB) Raised to Sell at StockNews.com
Pacific Biosciences of California ( NASDAQ:PACB – Get Free Report was upgraded by research analysts at StockNews.com to a “sell” rating in a note issued to investors on Tuesday. A number of other bro...
Quantexa News
02/25
Pacific Biosciences of California (NASDAQ:PACB) Stock Rating Upgraded by StockNews.com
Pacific Biosciences of California ( NASDAQ:PACB – Get Free Report was upgraded by StockNews.com to a “sell” rating in a research report issued on Tuesday. Get Pacific Biosciences of California alerts...
Quantexa News
02/25
Pacific Biosciences: Uncertain Federal Research Funding Latest Blow For Already-Battered Stock
Over the last four years, almost every light at the end of the tunnel for Pacific Biosciences (NASDAQ: PACB ) has turned out to be another oncoming train, as the company has been buffeted by multiple...
Quantexa News
02/25
https://seekingalpha.com/article/4761969-pacific-biosciences-uncertain-federal-research-funding-blow-already-battered-stock
Over the last four years, almost every light at the end of the tunnel for Pacific Biosciences (NASDAQ: PACB ) has turned out to be another oncoming train, as the company has been buffeted by multiple...
Quantexa News
02/26
Pacific Biosciences of California (NASDAQ:PACB) Rating Increased to Sell at StockNews.com
StockNews.com upgraded shares of Pacific Biosciences of California (NASDAQ:PACB – Free Report) to a sell rating in a research note issued to investors on Tuesday morning. Other research analysts have...
Quantexa News
02/28
Pacific Biosciences of California (NASDAQ:PACB) Upgraded at StockNews.com
StockNews.com upgraded shares of Pacific Biosciences of California ( NASDAQ:PACB – Free Report to a sell rating in a research report sent to investors on Tuesday morning. PACB has been the topic of s...
Quantexa News
03/02
IFP Advisors Inc Purchases 38,984 Shares of Pacific Biosciences of California, Inc. (NASDAQ:PACB)
IFP Advisors Inc lifted its position in shares of Pacific Biosciences of California, Inc. ( NASDAQ:PACB – Free Report ) by 24.0% during the fourth quarter, according to the company in its most recent...
Quantexa News
03/03
PacBio (PACB) Q4 Earnings Report Preview: What To Look For
PacBio (PACB) Q4 Earnings Report Preview: What To Look For Genomics company Pacific Biosciences of California (NASDAQ:PACB) will be announcing earnings results tomorrow after market hours. Here's wha...
Quantexa News
03/04
Bernstein Remains a Buy on Pacific Biosciences (PACB)
Bernstein analyst Eve Burstein maintained a Buy rating on Pacific Biosciences ( PACB – Research Report ) today and set a price target of $2.00. The company's shares closed yesterday at $1.32. Discov...
Quantexa News
03/07
Is Pacific Biosciences of California Inc (NASDAQ: PACB) A Suitable Stock For New Investors Today?
Pacific Biosciences of California Inc (NASDAQ:PACB) shares, rose in value, without any change to the previous day's close as strong demand from buyers drove the stock to $1.30. Actively observing the...
Quantexa News
03/10
Pacific Biosciences of California Inc (PACB): A Technical Analysis
PACB has 36-month beta value of 2.01. Analysts have mixed views on the stock, with 6 analysts rating it as a “buy,” 1 as “overweight,” 8 as “hold,” and 0 as “sell.” The public float for PACB is 243.51...
Quantexa News
03/11
A major move is in the offing as Pacific Biosciences of California Inc (PACB) market cap hits 380.67 million
A new trading day began on Monday, with Pacific Biosciences of California Inc (NASDAQ: PACB) stock price up 4.51% from the previous day of trading, before settling in for the closing price of $1.33. P...
